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Abstract 
Cellular proteases were first known for their roles in processing peptides such as signal 
peptides. Recent discoveries have begun to unravel their multifunctional roles in many 
other biological processes including blood pressure regulation and virus infection. 
However, the knowledge gathered thus far is still limited regarding the underlying 
mechanisms for these functions. Therefore, my thesis research focuses on elucidating the 
structural and molecular basis for the multiple functions of several critical cellular 
proteases (aminopeptidase A (APA), dipeptidyl peptidase 4 (DPP4), proprotein 
convertases (PPC) and lysosomal cysteine proteases (LCP)). 
 
APA is well known for its role in blood pressure regulation, but the lack of its structure is 
a major obstacle for designing APA-targeting agents for the treatment of hypertension, 
which affects about one third of US adults. My study determined the crystal structures of 
APA in complex with a variety of substrates and inhibitors, and elaborated the substrate 
specificity of APA in physiological contexts. The structural information sheds light on 
the blood pressure regulation by APA, and lays the foundation for developing novel APA 
inhibitors to treat hypertension. 
 
DPP4 was recently identified as the receptor for the newly emerged Middle East 
respiratory syndrome coronavirus (MERS-CoV). To provide insights into the origin of 
MERS-CoV, I investigated the receptor usage and cell entry of MERS-CoV in 
comparison with HKU4, a related bat coronavirus. I discovered that DPP4 is also the 
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receptor for HKU4. However, HKU4 failed to infect human cells because of its inability 
to use human cellular protease (e.g. PPC and LCP) for cell entry.  
 
PPC and LCP are critically involved in cell entry of many viruses. Here, I identified two 
residue differences between the spikes of MERS-CoV and HKU4 that account for their 
differential processes by human PPC and LCP, respectively. These results are critical for 
understanding the cross-species transmission of MERS-CoV, as well as for preventing 
the spread of related bat viruses. 
 
Taken together, the work presented in this thesis contributes to the overall understanding 
of the underlying mechanisms for diverse functions of cellular proteases in various health 
problems, and provides rationales for combating related health-threatening diseases.  
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1.1  Introduction 
Approximately 1 billion people or ∼26% of the adult population of the world are affected 
by hypertension1. Hypertension cannot be cured, but antihypertensive treatment can 
reduce cardiovascular morbidity and mortality. Despite the availability of many 
antihypertensive drugs, hypertension remains difficult to control. ∼20% of the 
hypertensive population are “resistant hypertension” patients, who do not respond well to 
three or more different antihypertensive drugs used at the same time2. This proportion is 
even greater when patients who do not respond well to two antihypertensive drugs used 
concurrently are included. Additionally, current antihypertensive drugs have lower 
efficacy in patients of African ancestry3,4 or patients with renal impairment or diabetes5,6. 
Consequently, the demand to develop new antihypertensive drugs with different 
mechanisms of action remains high. 
 
Blood pressure is regulated through both the central and systemic renin-angiotensin 
systems (RASs)7-9. Some hypertensive patients show hyperactivity in the central RAS but 
low activity in the systemic RAS. Hence, these patients are resistant to treatments 
targeting the systemic RAS10. The same set of peptidases play essential roles in both the 
central and systemic RASs (Fig. 1.1)11,12. Renin (also known as angiotensinogenase) 
cleaves the N-terminal 12 residues from the protein angiotensinogen to produce the 
peptide angiotensin I. Angiotensin-converting enzyme (ACE) then cleaves the C-terminal 
two residues from angiotensin I to produce angiotensin II. Aminopeptidase A (APA) 
cleaves the N-terminal aspartate from angiotensin II to produce angiotensin III. Finally, 
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aminopeptidase N (APN) cleaves the N-terminal arginine from angiotensin III to produce 
angiotensin IV. Interestingly, angiotensin peptides play different roles in the central and 
systemic RASs: in the systemic RAS, angiotensin II is the main effector peptide that 
increases blood pressure, whereas in the central RAS, angiotensin III plays this role13-15. 
Renin and ACE in the systemic RAS are among the main targets for antihypertensive 
drugs11. Recently, APA in the central RAS has been suggested as a new target for 
antihypertensive drugs16-21. In several types of hypertension animal models, brain-
targeting APA inhibitors, either directly injected into the brain or administered orally 
followed by brain distribution, have been shown to be effective in lowering blood 
pressure16-19. However, the design and development of this new class of antihypertensive 
drugs have been hindered by the lack of an atomic structure of APA. Like the crystal 
structures of renin and ACE22,23, the crystal structure of APA can inform therapeutic 
discoveries and aid in the control and treatment of hypertension. 
 
Mammalian APA is a member of the M1 family of zinc metalloenzymes and is widely 
expressed in many tissues, including the brain20,24. As a cell surface-anchored 
ectoenzyme, it preferentially cleaves acidic residues, either glutamate or aspartate, from 
the N-terminus of peptide substrates25. The catalytic mechanism of APA is believed to be 
similar to that of another zinc-dependent aminopeptidase in the same family, APN, whose 
structure our lab reported recently26. However, APA is unique among M1 family zinc 
metalloenzymes for favoring cleavage of acidic residues. Intriguingly, the substrate 
specificity of APA is modulated by calcium, a unique feature among all families of zinc 
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metalloenzymes. More specifically, calcium enhances the enzymatic activity of APA for 
cleavage of acidic residues while reducing its activity with basic residues27-31. The 
calcium-modulated substrate specificity of APA is deemed physiologically relevant 
because the concentrations of calcium that modulate APA activity are in the same range 
as those found in brain fluid (i.e. 1–2 mM)32. Mutagenesis studies have identified several 
residues in APA that may be involved in calcium modulation27-31. However, the structural 
mechanism for calcium-modulated substrate specificity of APA has remained a puzzle 
due to the lack of an atomic structure of APA. Understanding this mechanism will not 
only enrich our knowledge about the interesting APA enzymology but will also provide 
insights into central hypertension regulation by APA. 
 
Here, I have determined the crystal structures of the human APA ectodomain by itself 
and in complex with amino acids or peptidomimetic inhibitors. These structures illustrate 
detailed interactions between APA and its ligands. I have also identified a calcium-
binding site in APA and elucidated the structural basis for calcium-modulated APA 
activity. Additionally, this study reveals the structural basis for the different APA-
inhibiting potencies of peptidomimetic inhibitors. Taken together, these results provide 
an understanding of the substrate specificity and calcium modulation of APA in central 
hypertension regulation and will guide the development of a new class of brain-targeting 
APA inhibitors to treat hypertension. 
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1.2  Materials and Methods  
Reagents and Constructs  
The synthetic substrates glutamyl-p-nitroanilide (pNA), aspartyl-pNA, arginine-pNA, 
phenylalanine-pNA, and leucine-pNA and the peptidomimetic inhibitors bestatin and 
amastatin were from Sigma-Aldrich. pFastBac (Invitrogen) was described previously26. 
 
Protein Preparation and Crystallization  
The human APA ectodomain (residues 76–957; GenBank accession number 
AAA35522.1) was expressed and purified as described previously for porcine APN26. 
Briefly, the human APA ectodomain, containing an N-terminal honeybee melittin signal 
peptide and a C-terminal His6 tag, was expressed in insect cells using the Bac-to-Bac 
expression system (Invitrogen), secreted into cell culture medium, and subsequently 
purified on a HiTrap Chelating HP affinity column (GE Healthcare) and a Superdex 200 
gel filtration column (GE Healthcare). APA was concentrated to 10 mg/ml and stored in 
buffer containing 20 mM Tris (pH 7.4) and 200 mM NaCl. Crystallization of APA was 
set up using the sitting drop vapor diffusion method at 4 °C, with 2 µl of protein solution 
added to 2 µl of well buffer containing 1.6 M sodium citrate (pH 7.0). After 4 weeks, 
APA crystals were harvested in buffer containing 10% (v/v) glycerol and 1.6 M sodium 
citrate (pH 7.0) and flash-frozen in liquid nitrogen. 
 
Heavy atom derivatives of APA crystals were prepared by soaking crystals overnight in 
buffer containing 1 mM heavy atom (HgCl2 or K2PtBr6), 10% (v/v) glycerol, and 1.6 M 
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sodium citrate (pH 7.0). Crystals of APA-ligand complexes were prepared by soaking 
crystals overnight in buffer containing 8 mM ligand (amino acids or peptidomimetic 
inhibitors), 10% (v/v) glycerol, and 1.6 M sodium citrate (pH 7.0). Crystals of APA-
ligand complexes in the presence of calcium were prepared by soaking crystals overnight 
in buffer containing 8 mM ligand, 20 mM CaCl2, 10% (v/v) glycerol, and 1.6 M sodium 
citrate (pH 7.0). 
 
Data Collection and Structure Determination 
Data were collected at Advanced Light Source beamline 4.2.2 at a wavelength of 1.0003 
Å and at 100 K for native crystals. The crystal structure was determined with a mercury 
derivative and a platinum derivative by the multiple isomorphous replacement and 
anomalous scattering (MIRAS) method, with data collection conducted at wavelengths of 
1.0003 and 1.06883 Å. X-ray diffraction data were processed using HKL200033. The 
program SOLVE34 was used to find heavy atom sites and for MIRAS phasing. From a 
mercury-derivatized crystal, 14 mercury sites were identified. From a platinum-
derivatized crystal, 12 platinum sites were identified. The program RESOLVE was used 
for solvent flattening and automated model building35. The model was improved by 
iterative cycles of manual building in Coot 36 and refinement with CNS37and Refmac38. 
The similes files of ligands were loaded onto CCP4 Module Sketcher to generate CIF 
(crystallographic information file) files. The generated CIF files were used in CCP4 
refinement of APA-ligand complex structures. The CIF files were also converted to 
topology and parameter files in CNS using module cns_import_cif. The generated 
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topology and parameter files were used in CNS refinement of APA-ligand complex 
structures. Models of ligands were built based on Fo − Fc omit maps calculated in the 
absence of the ligands. For the APA native model, 97% of residues are in the favored 
regions of the Ramachandran plot, and 0.23% of residues are in the disallowed regions. 
 
Catalysis and Inhibition Assays 
APA catalytic activities were determined with 10 nM APA and 1 mM aminoacyl-pNA 
(amino acid-pNA) in 100 µl of 25 mM Tris-HCl buffer at pH 7.0 in the presence or 
absence of 2 mM CaCl2. The reactions were incubated at 37 °C for 30 min. Formation of 
product pNA was measured using a spectrophotometer and monitored at 405 nm. 
APA inhibition assays were carried out using a concentration gradient of the 
peptidomimetic inhibitors. Formation of product pNA was measured every 10 min. The 
IC50 is defined as the concentration of each inhibitor that led to 50% of maximal APA 
turnover of Glu-pNA. The Ki values for the inhibition assay were determined from the 
IC50 using the Cheng-Prusoff equation: Ki = IC50/(1+[S]/Km) 
 
1.3  Results  
Structural Determinations of APA and APA-Ligand Complexes 
Mammalian APA is a class II membrane protein with a short intracellular N-terminal tail, 
a single-pass transmembrane anchor, a small stalk, and a large C-terminal ectodomain24. 
The human APA ectodomain (residues 76–957) was expressed, purified, and crystallized 
in space group P6422 (a = 142.3 Å, b = 142.3 Å, and c = 237.3 Å), with one 
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molecule/asymmetric unit. The structure was determined by MIRAS using one mercury 
derivative and one platinum derivative. The final structural model was refined at 2.15 Å 
resolution (Fig. 1.2A and B). It contains residues 76–954 of the APA ectodomain (except 
for disordered loop 608–611) and 11 N-linked glycans. APA-ligand complexes were 
prepared by soaking each of the ligands (amino acids or peptidomimetic inhibitors) into 
APA crystals in the presence or absence of calcium. Their structures were determined by 
molecular replacement using the unliganded APA structure as the search template and 
were subsequently refined. Data and model statistics are listed in Table 1.1. 
 
Overall Architecture 
The human APA ectodomain has the same domain structures and arrangement as other 
M1 family zinc metalloenzymes (Figs. 1.2A and C, 1.3). It consists of four distinct 
domains: head (residues 633–954), side (residues 543–632), body (residues 294–542), 
and tail (residues 76–293) (Fig. 1.2A). The zinc-binding active site is located in a cavity 
created by the head, side, and body domains (Fig. 1.2B). The active site cavity of M1 
family zinc metalloenzymes can alternate between an open conformation for substrate 
loading or product unloading and a closed conformation for catalysis. These 
conformational changes are through a hinge-opening movement between the head 
domain and the other domains, accompanied by positional changes of catalytic residues26. 
All of the catalytic residues in the current APA structure are in their catalytically active 
positions (Fig. 1.4), suggesting that the APA structure captured in this study is in a closed 
conformation. However, the active site cavity of APA in the closed conformation is 
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significantly narrower than that of mammalian APN in the closed conformation (Fig. 
1.3A), suggesting that APA excludes large peptide substrates from accessing its active 
site and hence has a more restricted range of substrates compared with APN. 
The APA ectodomain forms a novel homodimer. In the crystal, there is only one 
molecule of the APA ectodomain in each asymmetric unit. However, two molecules from 
adjacent asymmetric units form the homodimer through their head domains (Fig. 1.2C), 
burying ∼1600 Å2 of accessible surface between them. These structural data are 
consistent with the previous observation that full-length mammalian APA forms a 
homodimer on cell surfaces25. Interestingly, although APA and APN both form a 
homodimer through their head domains, different regions in their head domains are 
involved in dimer formation, leading to completely different dimer interfaces (Figs. 1.2C 
and 1.3B). Dimer formation can increase the stability of APA and APN, both of which 
are ectoenzymes and face harsher environments than monomeric intracellular zinc 
metalloenzymes in the same family. Furthermore, the head-to-head dimer arrangements 
in both APA and APN can facilitate the closed-to-open conformational changes, during 
which the dimer interfaces are maintained and the membrane anchors move along the cell 
membrane. The different dimer arrangements of APA and APN suggest that a conserved 
dimer interface is not a prerequisite for the above functional benefits associated with 
dimer formation. 
 
Substrate Specificity 
To investigate the substrate specificity of APA, I determined the crystal structures of 
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APA complexed with amino acids or peptidomimetic inhibitors (Figs. 1.5A and B, 1.6A 
and B). APA and APN form the same interactions with the main chain of the N-terminal 
residue (P1 residue) of their ligands (Fig. 1.4), suggesting that the two enzymes share a 
common catalytic mechanism despite their modest sequence similarity. However, the S1 
pocket that accommodates the P1 side chain of ligands differs markedly between APA 
and APN, consistent with the different substrate specificities of the two enzymes. In 
general, the S1 pocket of APN is largely hydrophobic and prefers to accommodate 
hydrophobic amino acid side chains. In contrast, the S1 pocket of APA is polar and 
prefers to accommodate polar P1 side chains. In this study, I focused on the interactions 
between the S1 pocket of APA and the P1 side chains of ligands that are major 
determinants of the substrate specificity of APA. 
 
The S1 pocket of APA is well suited to accommodate the side chains of acidic residues. 
The carboxylate side chain of bound glutamate forms a strong salt bridge with Arg-887 
and a hydrogen bond with Thr-356 in the S1 pocket (Fig. 1.5A). These energetically 
favorable interactions are consistent with high APA activity on substrates with a P1 
glutamate (Fig. 1.5C). Mutation R887A causes a dramatic decrease in APA activity on 
substrates with a P1 glutamate through removal of the salt bridge (Fig. 1.5D). Mutation 
T356V also decreases APA activity on substrates with a P1 glutamate through removal of 
the hydrogen bond. In the absence of calcium, aspartate could not be soaked into the 
APA crystals, consistent with the relatively low APA activity on substrates with a P1 
aspartate in the absence of calcium. Presumably, the relatively short side chain of 
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aspartate would form a weak salt bridge with Arg-887, and thus, aspartate is less favored 
than glutamate by APA at the P1 substrate site. 
 
The S1 pocket also accommodates the side chains of basic residues (Fig. 1.5C). The 
guanidinium group of bound arginine forms a salt bridge with the side chain of Asp-221, 
a hydrogen bond with the main chain carbonyl of Glu-223, and another hydrogen bond 
with the side chain of Thr-356 (Fig. 1.5B). Mutation T356V decreases APA activity on 
substrates with a P1 arginine through removal of the hydrogen bond with the Thr-356 
side chain. Interestingly, compared with bound glutamate, the side chain of bound 
arginine points in a different direction, which reduces, but does not eliminate, charge 
repulsion with Arg-887 in the S1 pocket. Mutation R887A increases APA activity on 
substrates with a P1 arginine through elimination of the charge repulsion (Fig. 1.5D). 
These results are consistent with the observation that in the absence of calcium, arginine 
is less favored than glutamate, but more favored than aspartate, by APA at the P1 
substrate site (Fig. 1.5C). 
 
The S1 pocket discriminates against the side chains of neutral residues, as evidenced by 
low APA activity on substrates with a P1 leucine or phenylalanine (Fig. 1.5C). 
Accordingly, the amino acids leucine and phenylalanine were not observed bound to 
APA when soaked into the APA crystals. Instead, two peptidomimetic inhibitors, 
amastatin and bestatin, which contain a P1 leucine and phenylalanine, respectively, were 
successfully soaked into the APA crystals (Fig. 1.6A and B). The side chains of leucine 
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and phenylalanine both form hydrophobic interactions with the side chains of Phe-474 in 
the S1 pocket but also have unfavorable steric interactions with the polar residues in the 
S1 pocket (Fig. 1.6C and D). Steric hindrance from the P1 phenylalanine of bestatin even 
forces Arg-887 to adopt a different conformation (Fig. 1.6D). Therefore, residues with 
large neutral side chains are disfavored by APA at the P1 substrate site. 
 
Calcium Modulation 
To investigate the calcium-modulated substrate specificity of APA, I soaked calcium into 
the crystals of APA complexed with glutamate. The Fo − Fc map showed clear additional 
electron density in the S1 pocket of APA, which we interpreted to be a calcium ion and 
two calcium-coordinating water molecules (Fig. 1.7A). Our interpretation was based on 
the following observations. First, in the absence of calcium, the proposed calcium-
binding site is occupied by a water molecule (Fig. 1.7B). In the presence of calcium, the 
structural model was first refined with the water molecule occupying the proposed 
calcium-binding site, and the Fo − Fc map was then calculated. The Fo − Fc map 
contained significant positive electron density at this site, indicating a species more 
electron-rich than water. Second, in the absence of calcium, the water molecule 
occupying the proposed calcium-binding site is four-coordinate, forming hydrogen bonds 
with another water molecule, the Asp-221 side chain, the Glu-223 main chain carbonyl, 
and the bound glutamate (which is likely protonated due to the strong bifurcated salt 
bridge with Arg-887) (Fig. 1.7B). In the presence of calcium, two additional water 
molecules are observed, increasing the coordination number to six, consistent with 
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calcium replacing the water (Fig. 1.7A). Third, the geometry of the coordinated calcium 
is octahedral, consistent with the geometry for calcium coordination in other calcium-
binding proteins39,40. Finally, previous biochemical data show that mutation of Asp-221 
to other residues (e.g. alanine or asparagine) abolishes calcium modulation of APA 
activity30, which is consistent with our structural data. Therefore, I conclude that the 
calcium-binding site is located in the S1 pocket of APA adjacent to the P1 side chain of 
its ligands. 
 
As discussed above, in the absence of calcium, aspartate could not be observed in soaked 
APA crystals due to the relatively low binding affinity of aspartate. In contrast, in the 
presence of calcium, aspartate was observed following soaking into the APA crystals, 
consistent with the observation that calcium enhances the APA activity on substrates with 
a P1 aspartate (Fig. 1.5C). Using the same strategies that we used to identify the calcium-
binding site in the glutamate-bound APA structure, I again identified the same calcium-
binding site in the aspartate-bound APA structure (Fig. 1.7C). 
 
The identified calcium-binding site provides a structural basis for the calcium-modulated 
APA activity. Calcium enhances the APA-binding affinities of glutamate and aspartate by 
ligating their carboxylate side chains (Fig. 1.7A and C). In contrast, arginine could not be 
observed following soaking into calcium-bound APA crystals. The positively charged 
side chain of arginine cannot bind effectively due to charge repulsion with calcium, 
although it could be observed in soaked APA crystals in the absence of calcium (Figs. 
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1.5B and 1.7D). Therefore, the calcium ion that binds to the S1 pocket of APA enhances 
the binding of acidic residues at the P1 substrate site through coordination of their side 
chains but reduces the binding of basic residues at the P1 substrate site due to charge 
repulsion with their positively charged side chains. 
 
APA Inhibitors 
Two peptidomimetic inhibitors, amastatin and bestatin, are universal inhibitors of M1 
family zinc metalloenzymes. Here, I show that amastatin is a much more potent APA 
inhibitor than bestatin (Fig. 1.6F). By determining the crystal structures of APA 
complexed with each inhibitor, I elucidated the structural details of APA inhibition by 
these two inhibitors. First, as discussed above, the hydrophobic P1 side chains of both of 
the inhibitors have unfavorable steric interactions with the polar S1 pocket of APA. Due 
to its bulkier side chain, the P1 phenylalanine of bestatin has more severe steric clashes 
with the polar S1 pocket, forcing Arg-887 in the S1 pocket to adopt a different 
conformation (Fig. 1.6D). Second, amastatin contains four residues, whereas bestatin 
contains only two. The side chain of the C-terminal residue of amastatin (i.e. P3′ 
position) fits nicely into the S3′ subsite of APA, forming a strong bifurcated salt bridge 
with Arg-386 and a hydrogen bond with Asn-371 (Fig. 1.6E). In contrast, the shorter 
bestatin does not interact with the S3′ subsite of APA. These structural differences 
between the two inhibitors account for their different APA-inhibiting potencies. 
 
My study also has implications for the mechanisms of action of APA inhibitors that were 
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developed prior to the structure determination of APA. For example, RB150 is a prodrug 
for the potent APA inhibitor EC3318. RB150 is orally bioavailable, can cross the blood-
brain barrier, and is subsequently converted to EC33 in the brain (Fig. 1.8). EC33 has 
been shown to be an effective antihypertensive compound in animal models18. 
Interestingly, EC33 and glutamate share common structural features by containing a free 
N-terminal amine group and a negatively charged side chain of the same length. The free 
N-terminal amine group of EC33 likely binds to the APA active site in the same way as 
those of peptide substrates and analogs (Fig. 1.8). Although the side chains of EC33 and 
glutamate contain a sulfonic acid group and a carboxylate group, respectively, the former 
likely binds APA in the same way as the latter by forming salt bridges with Arg-887 and 
calcium in the S1 pocket. In addition, EC33 also contains a thiol group on the opposite 
end of the molecule to the amine group, in contrast to the carboxylate group of the C 
terminus of glutamate. It was hypothesized that the thiol group of EC33 directly interacts 
with the active site zinc18, but this hypothesis will need to be tested by crystallographic 
studies of APA complexed with EC33. Nevertheless, EC33 likely functions as a substrate 
analog and competitively binds to the APA active site. 
 
1.4  Discussion 
Hyperactivity in the central RAS has been implicated in the development and 
maintenance of hypertension7-9. In particular, a high-level central RAS, accompanied by a 
low-level systemic RAS, has been described in some hypertensive patients who are 
resistant to treatments targeting the systemic RAS10. The major effector peptide for blood 
    16 
pressure regulation in the brain is angiotensin III13-15. Angiotensin III is produced by the 
action of APA on angiotensin II and is converted to angiotensin IV by APN (Fig. 
1.1)11,12. To achieve central hypertension regulation, it is critical that the two different 
enzymes control these two angiotensin-converting steps. Thus, the substrate specificity of 
APA is essential for central hypertension regulation. How APA specifically cleaves only 
the N-terminal aspartate from angiotensin II but does not additionally cleave the 
subsequent arginine following the formation of angiotensin III has been a mystery. More 
intriguingly, the substrate specificity of APA is modulated by calcium at physiologically 
relevant concentrations. This study has elucidated the structural mechanisms for calcium-
modulated high APA activity on angiotensin II and low APA activity on angiotensin III, 
providing structural insights into central hypertension regulation by human APA. 
 
In this study, I determined the crystal structure of human APA by itself and in complex 
with a variety of ligands in the absence and presence of calcium. In the absence of 
calcium, the polar S1 pocket of APA forms salt bridges and hydrogen bonds with the 
charged side chains of both acidic and basic residues at the N-terminus of ligands, but it 
has unfavorable steric interactions with the hydrophobic side chains of neutral residues. 
Thus, in the absence of calcium, the S1 pocket of APA has evolved to accommodate both 
acidic and basic residues, but not neutral residues, at the N-terminus of ligands. In fact, in 
the absence of calcium, APA has higher activity on substrates with an N-terminal 
arginine than on those with an N-terminal aspartate. I further identified a calcium-binding 
site in the S1 pocket. When bound to APA, calcium is coordinated by the carboxylate 
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side chain of glutamate or aspartate but leads to charge repulsion with the guanidinium 
group of arginine. Thus, APA-bound calcium enhances the binding of glutamate and 
aspartate to APA and reduces the binding of arginine to APA. Consequently, in the 
presence of calcium, APA has much higher activity on substrates with an N-terminal 
aspartate (e.g. angiotensin II) than on those with an N-terminal arginine (e.g. angiotensin 
III). These unique and elegant structural mechanisms ensure that under physiological 
conditions, APA cleaves only angiotensin II, but not angiotensin III, providing regulation 
to central hypertension. 
 
This study also provides a structural platform for the design and development of novel 
APA inhibitors to treat hypertension. In several types of experimental and genetic 
hypertension animal models, orally active and brain-targeting APA inhibitors can 
modulate central RAS activity and reduce blood pressure without changing systemic 
RAS activity16-19. Furthermore, these APA inhibitors do not alter blood pressure in 
normotensive animals. The crystal structures of renin and ACE, two other peptidases in 
the RAS, have been successfully used in guiding rational drug design. The crystal 
structures of APA and its complexes with ligands can also be used in the rational design 
and development of novel antihypertensive drugs. More specifically, on the basis of the 
structural information of APA, we can design novel APA inhibitors with functional 
groups that explore and fit into different subsites in APA. In addition, using the structural 
framework of APA, we can also optimize and further develop existing APA inhibitors to 
enhance their potencies. To conclude, the structural information contained in this study 
    18 
regarding APA holds promise for the design and development of a new class of 
antihypertensive drugs. 
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Figure 1.1 Central and systemic RASs that together regulate blood pressure. 
In both the central and systemic RASs, renin cleaves angiotensinogen to produce 
angiotensin I, ACE converts angiotensin I to angiotensin II, APA converts angiotensin II 
to angiotensin III, and APN converts angiotensin III to angiotensin IV. Angiotensin II is 
the major effector peptide in the systemic RAS, whereas angiotensin III is the major 
effector peptide in the central RAS. 
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Figure 1.2 Overall structure of the human APA ectodomain. 
A, the human APA ectodomain contains four domains: head (cyan), side (brown), body 
(magenta), and tail (yellow). Residue numbers indicating domain boundaries are in 
parentheses. B, 2Fo − Fc electron density map of the zinc-binding site (contoured at 
1.5σ). C, structure of the dimeric APA ectodomain and model of dimeric full-length APA 
on the cell surface. Zinc is shown as a blue sphere. IC, intracellular tail; TM, 
transmembrane anchor  
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Figure 1.3 Structural comparisons of the conformation and dimer formation of 
porcine APN and human APA. 
A, structural alignment of APA (blue) and APN (green; Protein Data Bank code 4FKE), 
both of which are in the catalytically active and closed conformation. B, structure of the 
dimeric porcine APN ectodomain. 
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Figure 1.4 Structural comparisons of the active sites of porcine APN and human 
APA. 
A, interaction between the catalytic residues of APN (magenta) and the main chain of 
bound alanine (green; Protein Data Bank code 4FKH). B, interaction between the 
catalytic residues of APA (pink) and the main chain of bound glutamate (green). C, 
interaction between the catalytic residues of APN and the main chain of bound bestatin 
(green; Protein Data Bank code 4FKK). D, interaction between the catalytic residues of 
APA and the main chain of bound bestatin (green). 
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Figure 1.5 Substrate specificity of APA in the absence of calcium. 
A, detailed interactions between a glutamate side chain and the S1 pocket of APA. B, 
detailed interactions between an arginine side chain and the S1 pocket of APA. APA 
residues are in pink, and ligands are in green. Electron density maps of ligands 
correspond to Fo − Fc omit maps (contoured at 2.5σ) that were calculated in the absence 
of ligands. Models of APA-bound ligands were built based on these maps. Unit of 
distances is angstrom. C, relative catalytic activities of APA on different substrates 
(amino acid-pNA) in the absence or presence of calcium. The catalytic activity of APA 
on Glu-pNA in the absence of calcium was taken as 100%. Each bar shows the mean ± 
SEM (n = 3). D, relative catalytic activities of APA mutants on substrates. The catalytic 
activity of wild-type APA on Glu-pNA was taken as 100%. 
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Figure 1.6 APA-inhibiting mechanisms of peptidomimetic inhibitors. 
A, interactions between the inhibitor amastatin and APA. B, interactions between the 
inhibitor bestatin and APA. Detailed interactions between the inhibitors and APA 
residues are shown by arrows. Electron density maps of inhibitors correspond to Fo − Fc 
omit maps (contoured at 2.5σ) that were calculated in the absence of inhibitors. Models 
of APA-bound inhibitors were built based on these maps. C, detailed interactions 
between the P1 side chain of amastatin and the S1 pocket of APA. D, detailed 
interactions between the P1 side chain of bestatin and the S1 pocket of APA. E, detailed 
interactions between the P3′ side chain of amastatin and the S3′ subsite of APA. F, 
inhibition of APA catalytic activity by amastatin and bestatin. The catalytic activity of 
APA on Glu-pNA in the absence of inhibitor was taken as 100%. All values are mean ± 
SEM (n = 3). 
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Figure 1.7 Calcium-modulated substrate specificity of APA. 
A, observed calcium-binding site in the S1 pocket of glutamate-bound APA. The electron 
density map of calcium and two additional calcium-coordinating water molecules 
corresponds to the Fo − Fc omit map (contoured at 3.5σ) that was calculated with a water 
molecule occupying the calcium-binding site and in the absence of the two additional 
water molecules. B, in the absence of calcium, a water molecule occupies the calcium-
binding site in the S1 pocket of glutamate-bound APA. C, observed calcium-binding site 
in the S1 pocket of aspartate-bound APA. The electron density map was calculated in the 
same way as described for A, except that it was contoured at 3.0σ. D, modeled calcium-
binding site in the S1 pocket of arginine-bound APA. In the presence of calcium, arginine 
was not observed upon soaking into APA crystals. Instead, a structural model was 
constructed in which calcium replaced the water molecule occupying the calcium-binding 
site as in Fig. 1.5B. 
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Figure 1.8 Possible mechanisms of action of RB150, a brain-targeting APA 
inhibitor. 
RB150 is an orally bioavailable prodrug, can pass the blood-brain barrier, and is 
converted to its active form (EC33) inside the brain18. Potential interactions between 
EC33 and human APA are shown schematically. 
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Table 1.1 Data collection and refinement statistics of APA and its complexes with 
substrates and inhibitors. 
Values in parentheses are for the highest-resolution shell.  
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Chapter Two 
 
 
Receptor usage and cell entry of bat coronavirus HKU4 provide insight 
into bat-to-human transmission of MERS coronavirus 
Yang Yang*, Lanying Du*, Chang Liu*, Lili Wang, Cuiqing Ma, Jian 
Tang, Ralph S Baric, Shibo Jiang, Fang Li (*Co-first authors) 
Proc Natl Acad Sci USA 111: 12516-12521 (2014). 
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2.1 Introduction 
Since the summer of 2012, a novel coronavirus, Middle East respiratory syndrome 
coronavirus (MERS-CoV), has emerged from the Middle East and spread all over the 
world. MERS-CoV infection often leads to acute pneumonia, renal failure, and even 
death. As of June 9th, 2015, MERS-CoV had infected 1218 people, with a fatality rate of ∼37% (http://www.who.int/csr/don/09-june-2015-mers-korea/en/), and had demonstrated 
the capability for human-to-human transmission41,42. Alarmingly, coronavirus 
surveillance studies have suggested that MERS-CoV originated from bats. The genomic 
sequence of MERS-CoV is closely related to the sequences of two bat coronaviruses, 
HKU4 and HKU543-45, raising concerns over persistent bat-to-human cross-species 
transmission of the virus. Understanding the cross-species transmission mechanism of 
MERS-CoV is critical for evaluating long-term emerging disease potentials and for 
preventing and controlling the spread of bat-originated coronaviruses in humans. The 
clinical signs and epidemic patterns of MERS-CoV are reminiscent of the severe acute 
respiratory syndrome coronavirus (SARS-CoV), the etiological agent of the worldwide 
SARS epidemic in 2002-2003 that infected more than 8,000 people with a ∼10% fatality 
rate46,47. MERS-CoV poses a significant threat to global health and economy.  
 
Coronaviruses are enveloped and positive-stranded RNA viruses and can be divided into 
three major genera, α, β, and γ48. They mainly cause respiratory, gastrointestinal, and 
central nervous system diseases in mammals and birds. Coronaviruses recognize a wide 
range of receptors, including proteins and sialic acids49. Human NL63 respiratory 
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coronavirus (HCoV-NL63) from α-genus and SARS-CoV from β-genus both recognize 
angiotensin-converting enzyme 2 (ACE2) as their host receptor 50,51. Porcine respiratory 
coronavirus (PRCV) and some other coronaviruses from α-genus recognize 
aminopeptidase N (APN)52,53. Mouse hepatitis coronavirus (MHV) from β-genus 
recognizes carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1)54,55, 
although certain MHV strains also recognize heparan sulfate56,57. Some coronaviruses 
from each of the three genera recognize sugars58-61. MERS-CoV belongs to the β-genus 
and uses a cellular protease, human dipeptidyl peptidase 4 (DPP4), as its host receptor62. 
 
Receptor recognition has been established as an important determinant of the host range 
and tropism of coronaviruses48,63. An envelope-anchored trimeric spike protein mediates 
coronavirus entry into host cells by first binding to a host receptor through its S1 subunit 
and then fusing the host and viral membranes via its S2 subunit. The S1 subunit contains 
two independent domains, an N-terminal domain (NTD) and a C-terminal domain (CTD), 
both of which can potentially function as receptor-binding domains (RBD) (Fig. 2.3A)49. 
Specifically, coronavirus S1 CTDs can function as ACE2-, APN-, or heparan sulfate-
binding RBDs, whereas S1 NTDs can function as CEACAM1- or sugar-binding RBDs. 
To date, crystal structures have been determined for a number of coronavirus RBDs by 
themselves or in complex with their host receptors, revealing how coronaviruses have 
evolved to recognize host receptors and thereby traffic between different species64-68. It is 
not known which one of MERS-CoV S1 domains is the DPP4-binding RBD or the 
tertiary structure of MERS-CoV RBD, both of which can provide insights into the 
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receptor recognition of MERS-CoV.  
 
MERS-CoV spike protein shares 67% and 64% sequence similarity with the spike 
proteins in HKU4 and HKU5, respectively45, raising the possibility that HKU4 and 
HKU5 may also use DPP4 as their receptor. However, previous studies showed that 
receptor recognition by coronaviruses is sensitive to residue changes in coronavirus 
RBDs69. For example, one or two residue changes in the RBD of another bat-originated 
coronavirus, severe acute respiratory syndrome coronavirus (SARS-CoV), can dictate 
whether SARS-CoV uses human angiotensin-converting enzyme 2 as its receptor for 
efficient human infections64,69-71. Therefore, investigating the receptors of HKU4 and 
HKU5 is important for understanding their potential threats to human health and for 
delineating the causes of MERS-CoV infections in humans. 
 
In addition, coronavirus entry into host cells is limited not only by receptor recognition 
but also by membrane fusion. To fuse host and viral membranes, coronavirus spikes need 
to be cleaved at the S1/S2 boundary by host proteases72-76. The availability of these host 
proteases to coronaviruses and the specificities of these host proteases on coronavirus 
spikes can contribute to the host range and tropism of coronaviruses. Coronavirus-spike-
processing host proteases may include proprotein convertases from the virus-producing 
cells (e.g., furin), proteases from the extracellular environment (e.g., elastase), proteases 
on the cell surface of virus-targeting cells (e.g., type 2 transmembrane serine protease, or 
TMPRSS2), and proteases in the lysosomes of virus-targeting cells72,73 (e.g., cathepsin 
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L). Bat-originated and human-infecting coronaviruses MERS-CoV and SARS-CoV both 
use cell-surface protease TMPRSS2 and lysosomal protease cathepsins L for human cell 
entry, although proteases from the extracellular environment may also facilitate the cell 
entry process72-79. However, the mechanisms for human cell entry by bat coronaviruses 
are poorly understood, leaving a critical missing link in the bat-to-human transmission of 
coronaviruses. Therefore, examining the cell entry of HKU4 and HKU5 can provide 
novel knowledge of the causes of MERS-CoV (and SARS-CoV) infections in humans. 
 
In collaboration with Dr. Yaoqing Chen and Dr. Kanagalaghatta R. Rajashankar, we 
identified a defined RBD in MERS-CoV spike S1 subunit binds human DPP4 with high 
affinity and determined its crystal structure. By investigating the receptor usage and cell 
entry of HKU4 and HKU5, I also elucidated the mechanisms by which bat coronaviruses 
adapt to human cells during cross-species transmission events. These results provide 
valuable knowledge that can be used to evaluate emerging disease potentials of bat 
coronaviruses and to prevent and control the future spread of bat coronaviruses in 
humans. 
 
2.2 Materials and Methods 
Cell lines 
The HEK293T (human embryonic kidney), MRC-5 (human lung), and Tb1-Lu (Tadarida 
brasiliensis bat lung) cells were obtained from ATCC (www.atcc.org). Huh-7 (human 
liver) and Calu-3 (human lung) cells were kindly provided by Charles M. Rice at 
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Rockefeller University and Chien-Te K. Tseng at the University of Texas Medical 
Branch, respectively. These cell lines were maintained in Dulbecco’s modified Eagle 
medium (DMEM), supplemented with 10% FBS, 2 mM L-glutamine, 100 units/ml 
penicillin, and 100 µg/ml streptomycin (Life Technologies).  
 
Protein preparation and purification 
The S1 domains of MERS-CoV (residues 367–588; GenBank accession number 
AFS88936.1), HKU4 (residues 372–593; GenBank accession number ABN10839.1), 
HKU5 (residues 375–586; GenBank accession number ABN10875.1), and SARS-CoV 
(residues 306–527; GenBank accession number NC_004718) were expressed and 
purified as previously described for the SARS-CoV C-domain64,70,71. Briefly, the 
coronavirus spike C-domains containing an N-terminal honeybee melittin signal peptide 
and a C-terminal His6 tag was expressed in insect cells using the Bac-to-Bac expression 
system (Life Technologies), secreted into cell culture medium, and subsequently purified 
on a HiTrap Chelating HP affinity column (GE Healthcare) and a Superdex 200 gel 
filtration column (GE Healthcare). The proteins were concentrated to 10 mg/mL and 
stored in buffer containing 20 mM Tris (pH 7.4) and 200 mM NaCl. Fc-tagged 
coronavirus S1 domains were obtained by fusion of the human IgG4 Fc region to the C 
terminus of the proteins and were expressed using the same procedure as for the His6-
tagged S1 domain. The Fc-tagged S1 domains were purified sequentially on a HiTrap 
Protein G HP column (GE Healthcare) and Superdex 200 gel filtration column. 
Human DPP4 (hDPP4) ectodomain (residues 39–766; GenBank accession number 
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NP_001926.2) and bat DPP4 (bDPP4) ectodomain (residues 36–760; GenBank accession 
number KC249974) containing an N-terminal human CD5 signal peptide and a C-
terminal His6 tag were expressed and purified using the same procedure as for His6-
tagged coronavirus S1 domains. 
 
Pull-down assay using cell lysate 
HEK293T cells were transfected with either empty pcDNA3.1(+) vector or pcDNA3.1(+) 
vector containing the human DPP4 gene. At 48 h post-transfection, cells were harvested 
and lysed in PBS with 300 mM NaCl and 0.25% SDS. Cell lysate was mixed with 
MERS-CoV C-domain. The protein complex was then precipitated with nickel-
nitrilotriacetic acid (Ni-NTA) agarose (Thermo Scientific). DPP4 and MERS-CoV C-
domain contain a C-terminal hemagglutinin (HA) tag and His6 tag, respectively, and were 
detected by anti-HA and anti-His6 antibodies (Santa Cruz Biotechnology), respectively. 
 
Protein crystallization 
Crystallization of the MERS-CoV C-domain was set up using the sitting drop vapor 
diffusion method, with 2 μl protein solution added to 2 μl reservoir buffer containing 
27% (vol/vol) polyethylene glycol (PEG) 3350, 0.2 M MgCl2, and 0.1 M bis-Tris (pH 
7.0) at 20°C. After 2 weeks, crystals of the MERS-CoV C-domain were harvested in 
buffer containing 25% (vol/vol) ethylene glycol, 27% (vol/vol) PEG 3350, 0.2 M MgCl2, 
and 0.1 M bis-Tris (pH 7.0) and flash-frozen in liquid nitrogen. Heavy-atom derivatives 
of MERS-CoV C-domain crystals were prepared by soaking crystals for 15 min in buffer 
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containing 1 M NaI, 25% (vol/vol) ethylene glycol, 27% (vol/vol) PEG 3350, 0.2 M 
MgCl2, and 0.1 M bis-Tris (pH 7.0). 
 
Data collection and structure determination 
Data were collected at the Advanced Photon Source beamline 24-ID-C at 1.0716 Å for 
native crystals and 1.4586 Å for iodine-derivatized crystals. The crystal structure was 
determined using SIRAS (single isomorphous replacement with anomalous signal). X-ray 
diffraction data were processed using HKL200033. Sixteen iodine sites were identified 
with the program HYSS80 followed by phase refinement and solvent flattening with 
RESOLVE35. The model was built and refined with Refmac38 at 2.13 Å to a final Rwork 
and Rfree of 14.9% and 20.6%, respectively. In the final model of the MERS-CoV C-
domain, 98% of residues are in the favored regions of the Ramachandran plot, and 0% of 
residues are in the disallowed regions. 
 
AlphaScreen protein-protein binding assay 
The interactions between different coronavirus S1 domains and hDPP4 or bDPP4 were 
measured using AlphaScreen, as previously described81,82. Briefly, each of the Fc-tagged 
coronavirus S1 domains at 3 nM final concentrations was mixed with 100 nM His6-
tagged hDPP4 or bDPP4 in ½ AreaPlate (PerkinElmer) for 1 h at room temperature. 
AlphaScreen Nickel Chelate Donor Beads and AlphaScreen protein A acceptor beads 
(PerkinElmer) were added to the mixtures at final concentrations of 5 µg/ml. The 
mixtures were incubated at room temperature for 1 h and protected from light. The assay 
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plates were read in an EnSpire plate reader (PerkinElmer). 
 
Pull-down assay using purified protein 
Protein pull-down assay was carried out as previously described83. Briefly, 5 µg His6-
tagged hDPP4 or bDPP4 was mixed with each of the 5 µg Fc-tagged coronavirus S1 
domains. The formed complex was precipitated using Ni-NTA agarose (Thermo 
Scientific). The DPP4 and coronavirus S1 domains were separated by SDS/PAGE and 
detected by anti-His6 and anti-human IgG4 Fc antibodies (Santa Cruz Biotechnology), 
respectively. 
 
Dot blot binding assay 
Dot blot binding assay was carried out as previously described65. Briefly, 10 µg each of 
the Fc-tagged coronavirus S1 domains was dotted onto a nitrocellulose membrane. The 
membranes were dried completely and blocked with 5% skim milk at 37 °C for 1 h. Next, 
25 µg/ml His6-tagged hDPP4 or bDPP4 was preincubated alone or with 20 µg/ml goat 
anti-hDPP4 polyclonal antibodies (R&D Systems) at 37 °C for 1 h, added to the 
membrane, and incubated at 4 °C overnight. The membrane was then washed five times 
with phosphate-buffered saline with Tween-20 (PBST), incubated with anti-His6 mouse 
monoclonal IgG4 HRP conjugate antibody (Santa Cruz biotechnology) at 37 °C for 2 h, 
and washed five times with PBST. Finally, the bound proteins were detected using ECL 
plus (GE Healthcare). 
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Inhibition of MERS-CoV-spike-mediated pseudovirus entry by HKU4 RBD 
Pseudovirus cell entry assay was carried out as previously described84. Briefly, MERS-
CoV-spike-pseudotyped retroviruses expressing a luciferase reporter gene were prepared 
by cotranfecting HEK293T cells with a plasmid carrying Env-defective, luciferase-
expressing HIV-1 genome (pNL4-3.luc.R-E-) and a plasmid encoding MERS-CoV spike 
protein. The produced pseudovirus particles were harvested 72 h after transfection. 
HEK293T cells transiently expressing hDPP4 or bDPP4 were preincubated with gradient 
concentrations of each of the purified coronavirus S1 domains for 1 h at 37 °C and then 
infected by equal amounts of MERS-CoV-spike-pseudotyped retrovirus particles. After 
incubation for 5 h at 37 °C, medium was changed and cells were incubated for an 
additional 60 h. Cells were then washed with PBS and lysed. Aliquots of cell lysates were 
transferred to Optiplate-96 (PerkinElmer), followed by addition of luciferase substrate 
(Promega). Relative light units were measured using EnSpire plate reader (PerkinElmer). 
 
HKU4-spike-mediated pseudovirus entry into human and bat cells 
Retroviruses pseudotyped with MERS-CoV spike, HKU4 spike, or no spike (mock) were 
incubated with gradient concentrations of TPCK-treated trypsin (Sigma-Aldrich) for 10 
min at 25 °C, and 100 µg/ml soybean trypsin inhibitor (Sigma-Aldrich) was then added to 
stop the proteolysis reactions. Trypsin-treated pseudoviruses were used to spin-infect 
HKE293T cells (transiently expressing hDPP4, bDPP4, or no DPP4), Huh-7 cells 
(transiently expressing TMPRSS2 or no TMPRSS2), Calu-3 cells, MRC-5 cells, or Tb1-
Lu cells (transiently expressing hDPP4, bDPP4, or no DPP4) in 96-well plates at 1200 × 
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g for 2 h at 4 °C. After incubation for 5 h at 37 °C, medium was changed. Cells were 
incubated for an additional 60 h, then lysed and measured for luciferase activity. 
 
Neutralization of HKU4-spike-mediated pseudovirus entry by anti-hDPP4 
antibodies 
HEK293T cells expressing hDPP4, bDPP4, or no DPP4 were preincubated with 0, 2 
µg/ml, or 20 µg/ml goat anti-hDPP4 polyclonal antibodies (R&D Systems) at 37 °C for 1 
h and then infected by equal amounts of MERS-CoV-spike-pseudotyped retroviruses 
with no trypsin treatment or HKU4-spike-pseudotyped retroviruses after trypsin 
treatment. The infection procedure was the same as described earlier. 
 
Protease processing of MERS-CoV- or HKU4-spike-packaged pseudoviruses 
Retroviruses pseudotyped with MERS-CoV spike, HKU4 spike, or no spike (mock) were 
incubated with gradient concentrations of TPCK-treated trypsin (Sigma-Aldrich) for 10 
min at 25 °C, and 100 µg/ml soybean trypsin inhibitor (Sigma-Aldrich) was then added to 
stop the proteolysis reactions. Trypsin-treated pseudoviruses were concentrated in an 
Amicon Ultracentrifuge filter unit with 100-kDa cutoff (EMD Millipore, Billerica, MA). 
The pseudovirus samples were then subjected to Western blot analysis. The His6-tagged 
spikes were detected by antibody against their C-terminal His6 tag. 
 
Inhibition of pseudovirus entry into human cells by lysosome inhibitors 
Huh-7 cells were preincubated with 8 or 40 mM NH4Cl (Sigma-Aldrich) or 4 or 20 µM 
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E-64d (Sigma-Aldrich) at 37 °C for 1 h and then infected by HKU4- or MERS-CoV-
spike-pseudotyped retroviruses that had been pretreated or not pretreated with trypsin. 
The infection procedure was the same as described earlier. Huh-7 cells infected by 
retroviruses pseudotyped with no spike (mock) were used as control. 
 
2.3 Results 
Identification and functional characterization of MERS-CoV RBD 
Dr. Yaoqing Chen designed a construct of the MERS-CoV S1 C-domain (residues 367 to 
588), based on the sequence alignment of MERS-CoV and SARS-CoV S1 subunits (Fig. 
2.1). Although the two S1 subunits have low sequence similarity, sequence alignment 
was guided by conserved cysteines. Based on its crystal structure, SARS-CoV C-domain 
contains eight essential cysteines that form four disulfide bonds64. Our designed MERS-
CoV C-domain also contains eight cysteines, seven of which are conserved between 
SARS-CoV and MERS-CoV (Fig. 2.1). The MERS-CoV C-domain was expressed and 
purified using the protocol that we used for the SARS-CoV C-domain64,70,71. The protein 
was a monomer in solution, based on the gel filtration chromatography profile. 
 
I characterized the interactions between the recombinant MERS-CoV C-domain and 
hDPP4 on human cell surfaces, using pull down assay. The MERS-CoV C-domain pulled 
down hDPP4 from cells that express human DPP4 (Fig. 2.2). This result suggests that the 
recombinant MERS-CoV C-domain is the RBD that binds human DPP4. 
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Crystal structure of MERS-CoV RBD 
Having identified the MERS-CoV RBD, we further determined its crystal structure (Fig. 
2.3B and C). The MERS-CoV RBD was crystallized in space group P212121, with 2 
molecules per asymmetric unit. The structure was determined using an iodine derivative 
obtained by a short cryosoak85 and refined at a 2.13 Å resolution (Table 2.1). The two 
copies of MERS-CoV RBD occupying the same asymmetric unit have a small buried 
interface (∼500 Å2), consistent with the observation during protein purification that the 
MERS-CoV RBD is a monomer in solution. 
 
The crystal structure of the MERS-CoV RBD contains a core structure and an accessory 
subdomain (Fig. 2.3C). The core structure is a five-stranded antiparallel β-sheet with 
several short α-helices. The accessory subdomain lies on one edge of the core structure 
and consists of a four-stranded antiparallel β-sheet. The eight cysteines in the RBD form 
four disulfide bonds. Three of the disulfide bonds stabilize the core structure by 
connecting cysteine 383 to 407, 425 to 478, and 437 to 585; the remaining disulfide bond 
strengthens the accessory subdomain by connecting cysteine 503 to 526. The RBD also 
contains 2 glycans that are N-linked to Asn410 in the core structure and Asn487 in the 
accessory subdomain, respectively. We were able to trace all of the RBD residues (except 
for the N-terminal 12 residues) with an average B factor of 40.1 Å2. Overall, the MERS-
CoV RBD has a well-folded tertiary structure that is stabilized by disulfide bonds and 
glycans. 
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DPP4 is a functional receptor for HKU4 spike 
Based on the sequence alignment of MERS-CoV, HKU4 and HKU5 spikes, I designed a 
construct of HKU4 S1 domain (residues 372–593) and a construct of HKU5 S1 domains 
(residues 375–586), which correspond to the DPP4-binding RBD in MERS-CoV spike 
(residues 367–588) (Fig. 2.4A). I expressed and purified the S1 domains of four viruses 
(HKU4, HKU5, MERS-CoV, and SARS-CoV), as well as DPP4 ectodomain from two 
species (human and bat), using procedures described previously64,83. The two bat species 
from which HKU4 and HKU5 were isolated belong to the same family, but different 
genera43-45 (Fig. 2.4B). To understand coronavirus spike/DPP4 interactions, the DPP4 and 
coronavirus spike genes under investigation need to come from the same or similar bat 
species. Because the DPP4 genes from the above two bat species are unavailable, I chose 
the DPP4 gene from another bat species in the same genus as the one from which HKU5 
was isolated (Fig. 2.4B). All of the recombinant proteins were purified to high 
homogeneity (Fig. 2.5) and subsequently used in the following biochemical studies. 
 
Using three alternative approaches, I characterized the binding interactions between the 
S1 domain of each virus and DPP4 from each species. AlphaScreen protein-protein 
binding assay showed that whereas the MERS-CoV S1 domain bound hDPP4 with 
significantly higher affinity than it bound bDPP4, the corresponding HKU4 S1 domain 
bound bDPP4 slightly better than it bound hDPP4 (Fig. 2.6A). In contrast, the HKU5 S1 
domain did not bind hDPP4 or bDPP4. As a control, the SARS-CoV S1 domain only 
bound its own receptor human angiotensin-converting enzyme 2, but not hDPP4 or 
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bDPP4. Pull-down assay revealed that hDPP4 was more efficient than bDPP4 at pulling 
down the MERS-CoV S1 domain from solution, whereas both hDPP4 and bDPP4 pulled 
down the HKU4 S1 domain efficiently (Fig. 2.6B). In contrast, neither hDPP4 nor bDPP4 
pulled down the SARS-CoV or HKU5 S1 domain. Pseudovirus inhibition assay 
demonstrated that the HKU4 S1 domain, but not the HKU5 or SARS-CoV S1 domain, 
inhibited MERS-CoV-spike-mediated pseudovirus entry into HEK293T cells 
exogenously expressing hDPP4 or bDPP4. This indicates that the HKU4 S1 domain and 
MERS-CoV-spike-packaged pseudoviruses competed for the same DPP4 receptor on 
HEK293T cell surface (Fig. 2.6C). Taken together, these results showed that the HKU4 
S1 domain, but not the HKU5 S1 domain, binds both hDPP4 and bDPP4, and that the 
MERS-CoV S1 domain binds hDPP4 significantly better than it binds bDPP4, whereas 
the HKU4 S1 domain binds bDPP4 slightly better than it binds hDPP4. These results 
strongly suggest that HKU4 spike, but not HKU5 spike, uses DPP4 as its receptor and 
that the HKU4 S1 domain is the DPP4-binding RBD. 
 
MERS-CoV- and HKU4-spike-mediated viral entry into human cells 
To confirm that DPP4 is the receptor for HKU4 spike, I investigated whether HKU4 
spike could mediate viral entry into DPP4-expressing human cells. Because live HKU4 
virus has never been successfully cultured, it is not an option to use live HKU4 virus in 
this study. Instead, I performed an HKU4-spike-mediated pseudovirus entry assay. To 
this end, retroviruses pseudotyped with HKU4 spike were used to enter HEK293T cells 
exogenously expressing either hDPP4 or bDPP4 on their surface. Surprisingly, HKU4 
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spike failed to mediate pseudovirus entry into these DPP4-expressing HEK293T cells 
(Fig. 2.7A). As a comparison, MERS-CoV spike efficiently mediated pseudovirus entry 
into hDPP4-expressing HEK293T cells, but less efficiently into bDPP4-expressing 
HEK293T cells (Fig. 2.7B). However, when treated with trypsin, HKU4-spike-packaged 
pseudoviruses entered both hDPP4- and bDPP4-expressing HEK293T efficiently. As a 
comparison, trypsin treatment had little effect on MERS-CoV-spike-mediated 
pseudovirus entry into DPP4-expressing HEK293T cells. To validate these findings, we 
performed two control experiments to ensure that HKU4-spike-mediated entry depended 
on both HKU4 spike and DPP4. First, after trypsin treatment, HKU4-spike-pseudotyped 
retroviruses could not enter HEK293T cells not expressing DPP4 (Fig. 2.7A). Second, 
retroviruses not pseudotyped with HKU4 or MERS-CoV spike could not enter DPP4-
expressing HEK293T cells (Fig. 2.7C). Overall, these results support two conclusions: 
DPP4 is the functional receptor for HKU4 spike, and exogenous trypsin is needed for 
HKU4-spike-mediated, but not MERS-CoV-spike-mediated, pseudovirus entry into 
human cells. 
 
To further investigate the cell entry mechanism of HKU4, I repeated the pseudovirus 
entry assay using Huh-7 cells (human liver cells), Calu-3 cells (human lung cells), and 
MRC-5 cells (human lung cells), all of which endogenously express hDPP479,84,86. The 
results again showed that exogenous trypsin was needed for HKU4-spike-mediated, but 
not MERS-CoV-spike-mediated, pseudovirus entry into Huh-7, Calu-3, and MRC-5 cells 
(Fig. 2.8). Thus, our finding on the effects of trypsin on HKU4- and MERS-CoV-spike-
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mediated entry can be extended to different types of human cells. 
 
Neutralization of MERS-CoV- and HKU4-spike-mediated viral entry by DPP4-
targeting antibody 
Further confirmation that DPP4 is the receptor for HKU4 spike came from an 
examination of whether anti-hDPP4 polyclonal antibodies could competitively block the 
interactions between HKU4 spike and hDPP4. First, dot blot binding assay showed that 
the antibodies almost completely blocked the binding between HKU4 RBD and hDPP4 
and significantly inhibited the binding between MERS-CoV RBD and hDPP4 (Fig. 
2.9A). In contrast, the antibodies did not block the binding between HKU4 or MERS-
CoV RBD and bDPP4, suggesting that the antibodies did not target bDPP4. Second, 
pseudovirus neutralization assay revealed that the antibodies efficiently blocked both 
HKU4- and MERS-CoV-spike-mediated entry into hDPP4-expressing HEK293T cells, 
but not bDPP4-expressing cells (Fig. 2.9B). These results demonstrated that anti-hDPP4 
antibodies competed with HKU4 spike for the binding sites on hDPP4, further 
confirming that DPP4 is the functional receptor for HKU4 spike. 
 
Activation of MERS-CoV and HKU4 spikes by human cellular proteases 
What human cellular proteases process MERS-CoV spike, but not HKU4 spike? To 
address this question, I looked into all three stages in which human cellular proteases 
may play a role in coronavirus-spike-mediated cell entry. First, by performing Western 
blot on MERS-CoV- and HKU4-spike-packaged pseudoviruses, I found that MERS-CoV 
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spike, but not HKU4 spike, had been partially cleaved coming out of virus-producing 
HEK293T cells (Fig. 2.10). Moreover, HKU4 spike was cleaved by exogenous trypsin 
(Fig. 2.10). Thus, MERS-CoV spike, but not HKU4 spike, can be partially processed in 
virus-producing cells by human endogenous proteases. The processing may be achieved 
potentially by human proprotein convertases. Second, I carried out the pseudovirus entry 
assay using Huh-7 cells exogenously expressing human TMPRSS2 Huh-7 cells do not 
endogenously express TMPRSS287. The results showed that human TMPRSS2 enhanced 
MERS-CoV-spike-mediated, but not HKU4-spike-mediated, pseudovirus entry (Fig. 
2.11). Third, I explored the role of human lysosomal proteases in MERS-CoV- and 
HKU4-spike-mediated pseudovirus entry into Huh-7 cells, using two types of inhibitors: 
lysosomal acidification inhibitor NH4Cl and lysosomal protease inhibitor E-64d which 
inhibits lysosomal cathepsins L, B, H, etc88 (Fig. 2.12). MERS-CoV-spike-mediated entry 
was significantly inhibited by both NH4Cl and E-64d, revealing the critical role of 
lysosomal proteases in MERS-CoV-spike-mediated entry (the higher-than-baseline level 
of pseudovirus entry in the presence of NH4Cl or E-64d is probably a result of the prior 
partial processing of MERS-CoV spike during virus packaging and release). In contrast, 
these inhibitors showed little effect on HKU4-spike-mediated entry. Because HKU4 
spike fails to transduce the same cell line whose lysosomal proteases activate MERS-
CoV spike, HKU4 spike most likely cannot be activated by human lysosomal proteases. 
Overall, these results have demonstrated that MERS-CoV spike, but not HKU4 spike, can 
be processed by human cellular proteases from three different stages of virus infection: 
virus packaging and release, viral attachment to human cell surface, and viral 
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endocytosis. 
 
MERS-CoV- and HKU4-spike-mediated viral entry into bat cells 
Finally, I investigated whether HKU4 and MERS-CoV spikes can mediate pseudovirus 
entry into bat cells. I repeated pseudovirus entry assay, using Tb1-Lu cells (bat lung cells) 
that exogenously express hDPP4 or bDPP4. The results show that in the absence of 
trypsin, both HKU4 and MERS-CoV spikes efficiently mediated pseudovirus entry into 
Tb1-Lu cells, even though trypsin could further enhance HKU4-spike-mediated 
pseudovirus entry into Tb1-Lu cells (Fig. 2.13). In a control experiment, Tb1-Lu cells 
without exogenously expressed hDPP4 or bDPP4 failed to support MERS-CoV- or 
HKU4-spike-mediated pseudovirus entry, indicating a lack of endogenously expressed 
DPP4 in Tb1-Lu cells. These results revealed that in the presence of an appropriate 
receptor, activation by exogenous proteases is not a requirement for HKU4- or MERS-
CoV-spike-mediated pseudovirus entry into bat cells. 
 
2.4 Discussion 
In this part of my thesis study, after identifying the MERS-CoV RBD and determining its 
crystal structure, I further characterized the receptor usage and cell entry of MERS-
related bat coronaviruses HKU4 and HKU5 compared with bat-originated but human-
infecting MERS-CoV. Because HKU4 and HKU5 had never infected human cells, this 
study provided an opportunity to understand human cell adaptations by MERS-CoV. 
Through comparative analysis of these viruses, this study not only has identified the 
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functional receptor for HKU4 but also has revealed the functional differences between 
MERS-CoV and HKU4 spikes in their adaptations to use human receptor and cellular 
proteases for human cell entry. 
 
First, exploiting a combination of experimental approaches including AlphaScreen, 
protein pull down, dot blot hybridization, pseudovirus inhibition, pseudovirus entry, and 
antibody neutralization, this study has established DPP4 as the functional receptor for 
HKU4. Although HKU4 spike and bDPP4 are from two different bat species (Fig. 2.4B), 
the positive interaction between the two proteins suggests that HKU4 spike should also 
interact positively with bDPP4 from its own bat species. Indeed, my results show that 
both hDPP4 and bDPP4 are efficient receptors for HKU4 spike, although humans and 
bats are only remotely related species. In contrast, HKU5 spike does not use DPP4 as its 
receptor, despite sharing sequence similarity with MERS-CoV and HKU4 spikes. Again, 
this is unlikely because of the different bat species from which HKU5 and bDPP4 were 
isolated, but is a result of two deletions in the presumable DPP4-binding region of the 
HKU5 S1 domain (Fig. 2.4A). Moreover, whereas MERS-CoV spike binds hDPP4 with 
significantly higher affinity than it binds bDPP4, HKU4 spike slightly prefers bDPP4 
over hDPP4. MERS-CoV’s preference for hDPP4 over bDPP4 as its receptor is 
consistent with a recent finding89. Thus, it is likely that MERS-CoV spike has evolved to 
use hDPP4 efficiently but has become less effective in recognizing bDPP4, whereas 
HKU4 spike has not evolved adaptive mutations to promote efficient hDPP4 usage. 
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Second, using exogenous trypsin, lysosomal acidification and protease inhibitors, and 
pseudovirus entry into various types of human and bat cells, this study has revealed that 
human cellular proteases can activate MERS-CoV-spike-mediated, but not HKU4-spike-
mediated, pseudovirus entry into human cells. These human cellular proteases act on 
different stages of MERS-CoV-spike-mediated pseudovirus entry and include human 
endogenous proteases (e.g., proprotein convertases) acting during virus packaging and 
release, human TMPRSS2 acting during viral attachment to human cell surface, and 
human lysosomal cathepsins acting during viral endocytosis. Exogenous proteases 
contribute to, but are not essential for, MERS-CoV entry into human cells exogenously 
expressing low-affinity DPP4 homologs89. In contrast, an exogenous protease is essential 
for HKU4-spike-mediated entry into human cells. However, both MERS-CoV and HKU4 
spikes can mediate efficient pseudovirus entry into bat cells, suggesting that bat cellular 
proteases can process both MERS-CoV and HKU4 spikes. Because at this time, little is 
known about the functions of bat cellular proteases, future research will be needed to 
understand how coronavirus spikes mediate virus entry into bat cells. Nevertheless, this 
study indicates that MERS-CoV spike, but not HKU4 spike, has adapted to use human 
cellular proteases and thus has evolved the ability to mediate virus entry into human cells. 
 
These findings provide critical insight into the current MERS-CoV infections and raises 
concerns over potential future bat coronavirus infections in humans. DPP4-recognizing 
bat coronaviruses such as HKU4 pose a threat to human health because their spikes can 
potentially adapt to use human DPP4 and human cellular proteases for human cell entry. 
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Viral adaptation to human receptors enhances viral attachment to human cells, whereas 
viral adaptation to human cellular proteases reduces viral dependence on the extracellular 
environment. Both adaptation processes can facilitate coronaviruses to expand their host 
ranges and tropisms. These evolutionary changes may have already taken place during 
the bat-to-human transmission of MERS-CoV. Recent findings suggest that MERS-CoV 
has been circulating in camels for some time90-93. Viral adaptations to camel cells could 
have been an intermediate step toward viral adaptations to human cells. Regardless of 
whether the transmission to humans came directly from bats or indirectly through camels, 
the eventual viral adaptations to human cells may have contributed to the increased 
replication, transmission, and pathogenesis of MERS-CoV in humans. Our findings 
enhance understanding of the likely causes of MERS-CoV infections in humans, the 
potential health risks associated with DPP4-recognizing bat coronaviruses, and the 
mechanisms of cross-species transmissions of animal viruses in general. 
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Figure 2.1 Sequence comparisons of MERS-CoV and SARS-CoV S1 C-domains. 
Sequence alignment of MERS-CoV and SARS-CoV C-domains. Residues corresponding 
to C-domain core structures are in cyan, and residues corresponding to the proposed 
RBM region are in red. Cysteine residues are highlighted. Asterisks indicate positions 
that have fully conserved residues; colons indicate positions that have strongly conserved 
residues; periods indicate positions that have weakly conserved residues. 
  
    52 
 
 
 
Figure 2.2 Interactions between the MERS-CoV S1 C-domain and human DPP4. 
Pulldown of cell surface DPP4 by MERS-CoV C-domain. 293T cells were transfected 
with either empty vector or vector containing DPP4-HA gene. At 48 h posttransfection, 
cells were harvested and lysed. Cell lysate was mixed with the MERS-CoV C-domain 
containing a C-terminal His6 tag. The C-domain/DPP4 complex was then precipitated 
with Ni-NTA beads. 
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Figure 2.3 Crystal structure of the MERS-CoV S1 C-domain. 
(A) Domain structure of MERS-CoV S1 subunit that contains an N-terminal domain 
(NTD) and a C-domain. The boundaries of the C-domain and proposed receptor-binding 
motif (RBM) of MERS-CoV were determined by sequence and structural comparisons 
with the SARS-CoV S1 subunit (see Fig. 2.1). (B) Sequence and secondary structure of 
the MERS-CoV C-domain. Helices are drawn as cylinders, and strands are drawn as 
arrows. The disordered region is shown as a dashed line. (C) Crystal structure of the 
MERS-CoV C-domain. The core structure is in cyan, and the proposed RBM region is in 
red, disulfide bond-linked cysteine residues are shown as sticks in yellow, and N-linked 
glycans are shown as sticks in green. 
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Figure 2.4 Coronavirus S1 domains and DPP4. 
(A) Sequence alignment of the S1 domains from MERS-CoV, HKU4, and HKU5. 
Asterisks indicate positions that have fully conserved residues. Colons indicate positions 
that have strongly conserved residues. Periods indicate positions that have weakly 
conserved residues. DPP4-binding region in MERS-CoV RBD is in red. There are two 
deletions in the presumable DPP4-binding region of the HKU5 S1 domain. (B) 
Classification of bats from which the genes of HKU4, HKU5, and bDPP4 were isolated. 
 
    55 
 
Figure 2.5 SDS/PAGE analysis of purified recombinant proteins used in this study. 
These proteins include His6-tagged ectodomains of hDPP4 and bDPP4 and Fc-tagged S1 
domains from MERS-CoV, HKU4, HKU5, and SARS-CoV. The gel was stained by 
Coomassie Blue. 
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Figure 2.6 Binding interactions between HKU4 spike and DPP4. 
(A) AlphaScreen assay showing the direct binding interactions between the coronavirus 
spike S1 domains and hDPP4 or bDPP4. Binding affinity was characterized as 
AlphaScreen counts. Error bars indicate SEM (two-tailed t test, *P < 0.05, ***P < 0.001; 
n = 3). (B) Pull-down assay showing the direct binding interactions between the 
coronavirus S1 domains and hDPP4 or bDPP4. His6-tagged hDPP4 or bDPP4 was 
incubated with each of the Fc-tagged coronavirus S1 domains. The S1 domain/DPP4 
complex was then precipitated with nickel-nitrilotriacetic acid beads. Binding affinity 
was characterized as Western blotting on the precipitated Fc-tagged coronavirus S1 
domains. (C) Inhibition of MERS-CoV-spike-mediated pseudovirus entry by the HKU4 
S1 domain. HEK293T cells expressing hDPP4 or bDPP4 were preincubated with gradient 
concentrations of purified coronavirus S1 domains and then infected by MERS-CoV-
spike-packaged pseudoviruses expressing luciferase. The pseudovirus entry efficiency 
was characterized as luciferase activity accompanying the entry and normalized relative 
to the entry in the absence of any coronavirus S1 domain. Error bars indicate SEM (n = 
3). 
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Figure 2.7 HKU4- and MERS-CoV-spike-mediated pseudovirus entry into 
HEK293T cells.  
Retroviruses pseudotyped with HKU4 spike (A), MERS-CoV spike (B), or no spike 
(mock) (C) were incubated with gradient concentrations of trypsin and used to enter 
HEK293T cells (exogenously expressing hDPP4, bDPP4, or no DPP4, respectively). The 
pseudovirus entry efficiency was characterized as luciferase activity accompanying the 
entry. Error bars indicate SEM (n = 4). 
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Figure 2.8 HKU4-spike-mediated pseudovirus entry into human cells endogenously 
expressing DPP4. 
Retroviruses pseudotyped with HKU4 spike (A), MERS-CoV spike (B), or no spike 
(mock) (C) were incubated with gradient concentrations of trypsin and used to enter Huh-
7 cells, Calu-3 cells, or MRC-5 cells. The pseudovirus entry efficiency was characterized 
as luciferase activity accompanying the entry. Error bars indicate SEM (n = 4) 
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Figure 2.9 Anti-hDPP4 antibodies competitively block the interactions between 
HKU4 spike and hDPP4. 
(A) Dot blot hybridization assay showing the competitive inhibition of HKU4 S1 
domain/hDPP4 binding by anti-hDPP4 polyclonal antibodies. The Fc-tagged coronavirus 
S1 domain was dotted to the membrane first, and His6-tagged hDPP4 or bDPP4 was 
added later to the membrane after preincubation alone or with anti-hDPP4 antibodies. 
Binding affinity was characterized by the ensuing enzymatic color reactions. (B) 
Neutralization of HKU4-spike-mediated pseudovirus entry by anti-hDPP4 antibodies. 
Anti-hDPP4 anti- bodies strongly neutralized HKU4-spike-mediated pseudovirus entry 
into hDPP4-expressing HEK293T cells after treatment with 100 μg/ml trypsin. The 
antibodies also strongly neutralized MERS-CoV-spike-mediated pseudovirus entry into 
hDPP4-expressing HEK293T cells without trypsin treatment. The anti- bodies did not 
neutralize pseudovirus entry into bDPP4-expressing HEK293T cells. Error bars indicate 
SEM (n = 4). 
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Figure 2.10 Protease processing of MERS-CoV-spike- or HKU4-spike-packaged 
pseudoviruses. 
Retroviruses pseudotyped with MERS-CoV spike or HKU4 spike were treated with 
gradient concentrations of trypsin. The pseudovirus samples were then subjected to 
Western blot analysis. The His6-tagged spikes were detected by antibody against their C-
terminal His6 tag. 
 
 
 
 
 
 
    63 
 
Figure 2.11 Effects of human TMPRSS2 on HKU4- or MERS-CoV-spike-mediated 
pseudovirus entry into human cells. 
Retroviruses pseudotyped with HKU4 spike or MERS-CoV spike were pretreated with 
no trypsin, 20 µg/ml trypsin, or 100 µg/ml trypsin and used to enter Huh-7 cells or Huh-7 
cells exogenously expressing human TMPRSS2. The pseudovirus entry efficiency was 
characterized as luciferase activity accompanying the entry. Error bars indicate SEM 
(two-tailed t test, N.S., P > 0.05; n = 4). 
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Figure 2.12 Role of human lysosomal proteases in HKU4- and MERS-CoV-spike-
mediated entry into human cells. 
Huh-7 cells were first preincubated with lysosomal acidification inhibitor NH4Cl or 
lysosomal protease inhibitor E-64d at the indicated concentrations. Then the cells were 
infected by HKU4- or MERS-CoV-spike-pseudotyped retroviruses that had been 
pretreated or not pretreated with 100 µg/ml trypsin. The pseudovirus entry efficiency was 
characterized as luciferase activity accompanying the entry. Error bars indicate SEM (n = 
3). 
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Figure 2.13 HKU4- and MERS-CoV-spike-mediated pseudovirus entry into bat 
cells. 
Retroviruses pseudotyped with HKU4 spike (A), MERS-CoV spike (B), or no spike 
(mock) (C) were incubated with gradient concentrations of trypsin and used to enter Tb1-
Lu bat cells (exogenously expressing hDPP4, bDPP4, or no DPP4, respectively). The 
pseudovirus entry efficiency was characterized as luciferase activity accompanying the 
entry. Error bars indicate SEM (n = 4). 
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 MERS-RBD native NaI derivative 
Data Collection   
Space group P212121 P212121 
Cell dimensions   
a, b, c (Å) 45.361, 108.065, 124.287 45.822, 108.817, 124.328 
α, β, γ (°) 90, 90, 90 90, 90, 90 
Resolution (Å) 50-2.13 (2.17-2.13) 50-2.32 (2.36-2.32) 
Rsym or Rmerge 0.065 (0.459) 0.119 (0.574) 
I/σI 31.8 (2.0) 18.3 (2.0) 
Completeness (%) 97.8 (62.3) 98.5 (90.5) 
Redundancy 6.9 (4.3) 4.3 (2.7) 
 
Refinement 
  
Resolution (Å) 49.6-2.13   
No. reflections 34770  
Rwork/Rfree 0.149 / 0.206  
No. atoms 3701  
Protein 3261  
Ligand 120  
Water 320  
B-factors (Å2) 43.3  
Protein 40.1  
Ligand 104.3  
Water 53.1  
R.m.s derivations   
Bond lengths (Å) 0.008  
Bond angles (°) 1.33  
 
Table 2.1 Data collection and refinement statistics of MERS-CoV receptor-binding-
domain. 
Values in parentheses are for the highest-resolution shell. 
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Chapter Three 
 
 
Two mutations were critical for bat-to-human transmission of MERS 
coronavirus 
 
Yang Yang*, Chang Liu*, Lanying Du, Shibo Jiang, Zheng-Li Shi, Ralph S 
Baric, Fang Li (co-first authors) 
 
J Virol 89: 9119-9123 (2015).   
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3.1  Introduction 
Coronaviruses infect host cells through the activities of a viral-envelope-anchored spike 
protein94,95. The coronavirus spike is a member of the “class I” viral membrane fusion 
proteins that also include the virus-surface spike proteins from Ebola virus, influenza 
virus, and HIV 96-99. The ectodomain of the coronavirus spike consists of a receptor-
binding subunit S1 and a membrane-fusion subunit S2 (Fig. 3.1). The coronavirus spike 
is synthesized as a single chain precursor, and forms a clove-shaped trimer during the 
molecular maturation process100,101. To infect host cells, S1 binds to a host receptor for 
cell attachment102, and S2 subsequently undergoes a dramatic conformational change to 
fuse the viral and host membranes72-76. As I described in Chapter 2, the conformational 
change of S2 requires proteolytic cleavage at the S1/S2 boundary by one or more host 
proteases. The availability of these host proteases to coronaviruses is a critical 
determinant of viral tropism and pathogenesis72-76.  
 
Bats are considered the natural reservoir of Middle East respiratory syndrome 
coronavirus (MERS-CoV) because a number of coronaviruses, including HKU4, have 
been isolated from bats and are genetically closely related to MERS-CoV43-45,103. MERS-
CoV transmitted from bats to humans either directly or indirectly through intermediate 
hosts camels90,91. In the previous chapter, I have showed that HKU4 and MERS spikes 
both recognize host receptor dipeptidyl peptidase 4 (DPP4) for viral attachment to host 
cells104. Furthermore, only MERS-CoV spike, but not HKU4 spike, mediates viral entry 
into human cells because the former, but not the latter, can be activated by human 
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endogenous proteases (i.e. human proprotein convertases (hPPC), cell-surface proteases, 
and lysosomal cysteine proteases (LCP)). Here I further identified two residue differences 
between the two spikes that account for their different capability to mediate viral entry 
into human cells. These results have revealed a likely evolutionary pathway for the 
emergence of MERS-CoV as a human pathogen. 
 
3.1 Materials and Methods 
Cell lines and plasmids 
HEK293T, MRC-5, Tb1-Lu and Huh-7 cells were cultured as described in Chapter 2. 
RSKT (Rhinolophus sinicus bat kidney) cell line was established in-house105, and 
cultured in Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% fetal 
bovine serum (FBS), 2 mM L-glutamine, 100 units/ml penicillin, and 100 µg/ml 
streptomycin (Life Technologies). 
 
The genes of MERS-CoV spike (GenBank accession number AFS88936.1) with a C-
terminal C9 tag, HKU4 spike (GenBank accession number ABN10839.1) with a C-
terminal C9 tag, human DPP4 (GenBank accession number NP_001926.2) with a C-
terminal HA tag, and bat DPP4 (GenBank accession number KC249974) with a C-
terminal HA tag were each cloned into pcDNA3.1(+) vector (Life Technologies). 
Mutations in MERS-CoV spike and HKU4 spike were carried out using site-directed 
mutagenesis and validated by automated DNA sequencing (University of Minnesota 
Genomics Center). 
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Pseudovirus production 
MERS-CoV- or HKU4-spike-pseudotyped retroviruses were generated as previously 
described104. Briefly, HEK293T cells were co-transfected with a plasmid carrying Env-
defective, luciferase-expressing HIV-1 genome (pNL4-3.luc.R-E-) and a plasmid 
encoding MERS-CoV spike or HKU4 spike using Lipofectamine 3000 reagent (Life 
Technologies) according to the manufacturer’s instructions. Supernatants containing 
pseudoviruses were harvested 72 h after transfection, and centrifuged at 1200 × g for 10 
min to remove cell debris. 
 
Western blot analysis of HKU4 and MERS-CoV pseudoviruses 
HKU4 and MERS-CoV pseudoviruses were packaged in HEK293T cells as describe 
above. Seventy-two hours after transfection, retroviruses pseudotyped with MERS-CoV 
or HKU4 spike were harvested and concentrated using Amicon Ultracentrifuge filter 
units with a 100-kDa cutoff (EMD Millipore). The pseudovirus particles were then 
subjected to Western blot analysis. The C9-tagged spikes were detected using anti-C9 tag 
monoclonal antibody. The expression levels of HKU4 and MERS-CoV spikes in 
pseudovirus particles were quantified using ImageJ software (National Institutes of 
Health). 
 
Pseudovirus entry into human and bat cells  
MERS-CoV- or HKU4-spike-mediated pseudovirus entry was carried out as previously 
described104. Briefly, retroviruses pseudotyped with wild type or mutant MERS-CoV 
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spike, wild type or mutant HKU4 spike, or no spike (mock) were used to spin-infect 
HKE293T cells transiently expressing human DPP4, RSKT cells, Tb1-Lu cells 
transiently expressing bat DPP4, Huh-7 cells, or MRC-5 cells in 96-well plates at 1200 × 
g for 2 h at 4°C. The medium was replaced with serum-free DMEM (pre-warmed to 
37°C) in the presence or absence of 40 µg/ml TPCK-treated trypsin (Sigma-Aldrich). 
After incubating at 37°C for 10 min, DMEM supplemented with 75 µg/ml soybean 
trypsin inhibitor (Sigma-Aldrich) was added to neutralize trypsin. Cells were incubated at 
37°C for 12 h, and medium was replaced with fresh DMEM. 48 h later, cells were 
washed with PBS and lysed. Aliquots of cell lysates were transferred to Optiplate-96 
plate (PerkinElmer), followed by addition of luciferase substrate (Promega). Relative 
luciferase units (RLU) were measured using EnSpire plate reader (PerkinElmer). The 
expression levels of the spikes, all of which contain a C-terminal C9 tag, were measured 
by Western blot and used to normalize the entry efficiencies106. 
 
Inhibition of pseudovirus entry into human and bat cells using protease inhibitors  
For proprotein convertase inhibition, HEK293T cells were co-transfected with plasmid 
pNL4-3.luc.R-E- and a plasmid encoding MERS-CoV spike or HKU4 spike. Five hours 
post-transfection, medium was replaced with DMEM supplemented with 10 µM or 50 
µM dec-RVKR-CMK (Enzo Life Sciences). Pseudoviruses were harvested 72 h after 
transfection and used to infect HEK293T cells transiently expressing human DPP4.  
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For lysosomal cysteine protease inhibition, HEK293T cells transiently expressing human 
DPP4, RSKT cells or Tb1-Lu cells transiently expressing bat DPP4 were pre-incubated 
with 2 µM or 10 µM E-64d (Sigma-Aldrich) at 37°C for 1 h, and then spin-infected by 
HKU4-spike-pseudotyped or MERS-CoV-spike-pseudotyped retroviruses at 1200 × g for 
2 h at 4°C. The medium was replaced with DMEM (pre-warmed to 37°C) in the presence 
or absence of E-64d (2 µM or 10 µM). Cells were then incubated at 37°C for 12 h, and 
medium was replaced with fresh DMEM. 48 h later, cells were lysed and measured for 
luciferase activity. 
 
Western blot analysis of spike cleavage by lysosomal cysteine proteases 
Lysosomal cysteine proteases were prepared as previously described107-109. Briefly, 
HEK293T cells or Tb1-Lu cells were transfected with plasmids encoding MERS-CoV 
spike or HKU4 spike using Lipofectamine LTX transfection reagent (Life Technologies) 
according to the manufacturer’s instructions. 48 h after transfection, cells were harvested, 
washed with PBS and lysed by sonication in 100 mM sodium acetate, 1 mM 
dithiothreitol (DTT), 0.1% Triton X-100, pH 5.0, supplemented with 100 µM camostat 
mesylate (Sigma-Aldrich), 5 µM pepstatin A (Sigma-Aldrich), 1 mM EDTA (Sigma-
Aldrich) and 1 mM EGTA (Sigma-Aldrich) to inhibit serine-, aspartate- and metallo-
proteases, respectively. Cell lysates were then incubated at 37°C for 30 min, and 
subjected to Western blot analysis. The C9-tagged spikes were detected using anti-C9 tag 
monoclonal antibody (Santa Cruz Biotechnology). 
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3.2 Results 
Identification of two protease motifs in MERS-CoV and HKU4 spikes  
By comparing the sequences of MERS-CoV and HKU4 spikes, I identified two regions in 
MERS-CoV spike that serve as human protease target motifs, but differ from the 
corresponding regions in HKU4 spike (Fig. 3.1). The first region has been established as 
a signature motif for human proprotein convertases (hPPC motif)110,111, but the critical 
Arg748 in MERS-CoV spike corresponds to Ser746 in HKU4 spike, which deviates from 
the hPPC motif. The second region has been established as a signature motif for human 
lysosomal cysteine proteases (hLCP motif)112,113, but the motif Ala763-Phe764-Asn765-
His766) (AFNH) in MERS-CoV spike corresponds to Asn762-Tyr763-Thr764-Ser765 
(NYTS) in HKU4 spike, which likely introduces an N-linked glycosylation site and may 
potentially block the access of human lysosomal cysteine proteases. Therefore, these 
residue differences in the hPPC and hLCP signature motifs between MERS-CoV and 
HKU4 spikes may affect the spikes’ capability to mediate viral entry into host cells, and 
thus may hold the key to the host ranges of the two viruses. 
 
Re-engineering two protease sites in HKU4 
To evaluate the potential genetic changes required for HKU4 to infect human cells, I re-
engineered HKU4 spike, aiming to build its capacity to mediate viral entry into human 
cells. To this end, I introduced two single mutations, S746R and N762A, into HKU4 
spike. The S746R mutation was expected to restores the hPPC signature motif in HKU4 
spike, whereas the N762A mutation likely disrupts the N-linked glycosylation site in the 
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hLCP signature motif in HKU4 spike. To confirm that the S746R mutation restored the 
hPPC motif, I produced retroviruses pseudotyped with HKU4 spike (hereafter referred to 
as HKU4 pseudoviruses) in human cells, and showed that HKU4 spike containing the 
S746R mutation was partially cleaved during the molecular maturation process, whereas 
wild type HKU4 spike remained intact (Fig. 3.2A). Confirming that the N762A mutation 
disrupted the N-linked glycosylation site in the hLCP motif was technically challenging 
because of the large size and heavy glycosylation of HKU4 spike (trimeric HKU4 spike 
has 78 predicted N-linked glycosylation sites and a total molecular weight of ~530 kDa). 
Nevertheless, I managed to identify a slight downward shift of HKU4 spike with N762A 
mutation using Western blot analysis (Fig. 3.2B), consistent with successful removal of 
the N-linked glycosylation site. 
 
To further confirm removing the N-linked glycosylation site made HKU4 spike cleavable 
by hLCP, I first expressed HKU4 spike on the surface of HEK293T cells, and prepared 
hLCP by lysing HEK293T cells and inhibiting the activities of the other human 
endogenous proteases (serine-, aspartate- and metallo-proteases)107-109. Subsequently, I 
treated HEK293T-cell-surface HKU4 spike with hLCP, and performed Western blot to 
detect the cleavage state of wild type and mutant HKU4 spikes (Fig. 3.3A). Wild type 
HKU4 spike remained intact, whereas mutant HKU4 spike bearing the re-engineered 
hLCP motif underwent significant cleavage. Thus the re-engineered hLCP motif allowed 
HKU4 spike to be processed by hLCP 
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HKU4-spike-mediated entry into human cells 
I then examined the capability of mutant HKU4 spikes to mediate viral entry into human 
cells. HKU4 pseudoviruses were packaged in HEK293T cells (human embryonic kidney 
cells), and were used to infect HEK293T target cells that exogenously express human 
DPP4 receptor. In the absence of exogenous protease trypsin, HKU4 pseudoviruses 
bearing either the re-engineered hPPC motif or the re-engineered hLCP motif were able 
to enter HEK293T cells, whereas HKU4 pseudoviruses bearing both of the re-engineered 
human protease motifs entered HEK293T cells as efficiently as when activated by 
exogenous trypsin (Fig. 3.4A). In contrast, wild type HKU4 pseudoviruses failed to enter 
HEK293T cells. Similar results were obtained when two other human cell lines were 
used: Huh-7 (human liver cells) and MRC-5 (human lung cells) both of which 
endogenously express human DPP4 receptor (Fig. 3.5A and B). Therefore, the re-
engineered hPPC and hLCP motifs enabled HKU4 spike to be activated by human 
endogenous proteases, allowing HKU4 pseudoviruses to bypass the need for exogenous 
proteases to enter human cells. These results reveal that HKU4 spike only needs two 
single mutations at the S1/S2 boundary to gain the full capacity to mediate viral entry 
into human cells. 
 
To confirm the functions of the re-engineered human protease motifs in HKU4 spike, I 
used protease inhibitors to probe the human proteases that activate HKU4-spike-mediated 
viral entry into human cells. Human proprotein convertase inhibitor, Dec-RVKR-CMK, 
and lysosomal cysteine protease inhibitor, E-64d, both blocked human cell entry of 
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HKU4 pseudoviruses bearing the re-engineered hPPC motif and the re-engineered hLCP 
motif, respectively (Fig. 3.4B). This result verified that the gained capability of HKU4 
pseudoviruses to enter human cells was due to the re-engineered human protease motifs 
in HKU4 spike. Taken together, these data confirm that the two mutations in the re-
engineered human protease signature motifs allow HKU4 spike to be cleaved by human 
proprotein convertases and lysosomal cysteine proteases, respectively. 
 
MERS-CoV-spike-mediated entry into human cells 
To investigate the functions of the two human protease motifs in MERS-CoV-spike-
mediated viral entry into human cells, I re-engineered MERS-CoV spike in the opposite 
way, aiming to reduce or eliminate its capability to mediate viral entry into human cells. 
To this end, I introduced a single mutation R748S and a triple mutation 
A763N/F764Y/N765T into MERS-CoV spike. The R748S mutation destroyed the hPPC 
signature motif in MERS-CoV spike (Fig. 3.2A), whereas the triple mutation 
A763N/F764Y/N765T successfully added an N-linked glycosylation site to the hLCP 
signature motif in MERS-CoV spike (Fig. 3.2B). When expressed on the surface of 
HEK293T cells, MERS-CoV spike bearing the mutant hLCP motif resisted digestion 
when incubated with human lysosomal cysteine proteases (Fig. 3.3B). To prevent the 
cleavage during the molecular maturation process, MERS-CoV spike also contained the 
mutant hPPC motif, such that the hLCP motif became the only potential cleavage site in 
the spike. MERS-CoV pseudoviruses bearing either the mutated hPPC motif or the 
mutated hLCP motif demonstrated decreased capability to enter three types of human 
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cells (Fig. 3.4C for HEK293T cells; Fig. 3.5C and D for Huh-7 and MRC-5 cells, 
respectively). MERS-CoV pseudoviruses bearing both of the mutated human protease 
motifs were unable to enter human cells. Exogenous trypsin was able to fully rescue the 
capability of mutant MERS-CoV pseudoviruses to enter human cells. Moreover, PPC 
inhibitor and LCP inhibitor both blocked human cell entry of wild type MERS-CoV 
pseudoviruses, but had no effect on human cell entry of MERS-CoV pseudoviruses 
bearing the mutant hPPC motif or the mutant hLCP motif, respectively (Fig. 3.4D). Thus, 
the mutations in the hPPC and hLCP motifs together eliminate MERS-CoV-spike 
mediated viral entry into human cells. These results demonstrate that the two functional 
human protease motifs in MERS-CoV spike played a critical role in the bat-to-human 
transmission of MERS-CoV. 
 
HKU4- and MERS-CoV-spike-mediated entry into bat cells 
After examining HKU4- and MERS-CoV-spike mediated viral entry into human cells, I 
investigated how these spikes mediate viral entry into bat cells. Because of the low 
transfection efficiency of bat cells, I was unable to package pseudoviruses in bat cells. 
Instead, I packaged HKU4 and MERS-CoV pseudoviruses in HEK293T cells and 
subsequently performed HKU4- and MERS-CoV-spike-mediated pseudovirus entry into 
two types of bat cells: RSKT and Tb1-Lu cells (Fig. 3.6). Wild type HKU4 pseudoviruses 
entered bat cells efficiently, whereas HKU4 pseudoviruses bearing the re-engineered 
hLCP motif (which removed the N-linked glycosylation site) demonstrated enhanced 
capability to enter bat cells (Fig. 3.6A and B). On the other hand, wild type MERS-CoV 
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pseudoviruses entered bat cells efficiently, whereas MERS-CoV pseudoviruses bearing 
the mutant hLCP motif (which added the N-linked glycosylation site) demonstrated 
reduced, but still significant, capability to enter bat cells (Fig. 3.6C and D). Moreover, 
most of HKU4 and MERS-CoV-spike-mediated pseudovirus entry into bat cells could be 
blocked by the LCP inhibitor, also suggesting that bat lysosomal cysteine proteases 
activate coronavirus spikes bearing a glycosylated hLCP motif (Fig. 3.6). These results 
indicate that unlike human lysosomal cysteine proteases, bat lysosomal cysteine proteases 
are capable of recognizing and cleaving efficiently the hLCP motif containing a 
glycosylation site. The functional differences between human and bat lysosomal cysteine 
proteases account for HKU4 spike’s capability to mediate viral entry into only bat cells, 
but not human cells. 
 
3.3 Discussion 
Understanding the molecular mechanisms for cross-species transmissions of viruses is 
critical for evaluating their emerging disease potentials and for preventing and controlling 
their spread in human populations. In this part of my thesis research, I examined the 
different cell entry activities of the spike proteins from human-infecting MERS-CoV and 
a closely related bat coronavirus HKU4. Although MERS-CoV and HKU4 spikes share a 
high sequence homology and recognize the same host DPP4 receptor, only MERS-CoV 
spike, but not HKU4 spike, mediates viral entry into human cells. This study revealed 
that introduction of two single mutations, S746R and N762A, into HKU4 spike at the 
S1/S2 boundary fully instilled its capability to mediate viral entry into human cells. 
    81 
MERS-CoV spike already contained both of these mutations, explaining why MERS-
CoV is capable of infecting human cells. Thus these two mutations in the spike are 
essential for MERS-CoV to transmit from bats to humans by allowing MERS-CoV spike 
to be activated by human cellular proteases. Viral adaptation to human cellular proteases 
is critical for viral infection of human cells because human cellular proteases, particularly 
lysosomal proteases, are more reliable sources than some extracellular proteases to 
activate virus entry. Previous research also identified two mutations in SARS-CoV spike 
that led SARS-CoV to transmit from palm civets to humans64,69,70,114. These mutations 
increased SARS-CoV spike’s capability to bind human receptor angiotensin-converting 
enzyme 2. Thus, different entry factors appear to have played the most critical roles in the 
cross-species transmission of MERS-CoV and SARS-CoV: adaption to human cellular 
proteases by MERS-CoV and adaption to human receptor by SARS-CoV. Although 
MERS-CoV spike might also need to adapt to human DPP4 receptor upon infecting 
human cells104,115, such adaptations might only have incremental effects on the infectivity 
of MERS-CoV in human cells. In contrast, the two mutations adaptive to human cellular 
proteases transformed MERS-CoV spike from completely lacking to fully owning the 
capacity to mediate viral entry into human cells, and thus they likely played the most 
critical role in the bat-to-human transmission of MERS-CoV. 
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Figure 3.1 Domain structure of MERS-CoV and HKU4 spike proteins. 
The spikes contain a receptor-binding S1 subunit, a membrane-fusion S2 subunit, a 
transmembrane anchor (TM), and an intracellular tail (IC). S1 contains the receptor-
binding domain (RBD) that binds DPP4 receptor. S2 contains the fusion peptide (FP), 
heptad repeat 1 (HR1), and heptad repeat 2 (HR2), all of which are essential structural 
elements for the membrane fusion process. The S1/S2 boundary in MERS-CoV spike 
contains two established human protease motifs that are recognized by human proprotein 
convertases (hPPC) and lysosomal cysteine proteases (hLCP), respectively. Sequence 
alignments of these regions in MERS-CoV and HKU4 spikes are shown, with the critical 
residue differences labeled in red. Arrows indicate the cleavage sites in MERS-CoV 
spike by human proteases. 
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Figure 3.2 Characterization of two protease motifs in MERS-CoV and HKU4 spike 
proteins. 
(A) Western blot analysis of HKU4 and MERS-CoV spikes in pseudovirus particles. The 
incorporations of wild type (WT) and mutant HKU4 and MERS-CoV spikes into 
pseudovirus particles were measured by Western blot using antibody against their C-
terminal C9 tags. Plots below the Western blot images correspond to quantifications of 
the band intensities from the cleaved and uncleaved spikes combined. The numbers 
below the plots indicate the relative amount of spikes incorporated into pseudovirus 
particles compared to wild type HKU4 and MERS-CoV spikes, respectively. All 
quantifications were done using ImageJ software (National Institutes of Health). (B) 
Glycosylation state of HKU4 spike at the hLCP motifs. HEK293T cells exogenously 
expressing wild type (WT) and mutant HKU4 spikes were lysed and subjected to western 
blot analysis. To improve the separation of large molecular weight spikes, 3-8% 
NuPAGE Tris-Acetate Gels (Life Technologies) were used for gel electrophoresis. To 
improve the accuracy of the result, each of the mutant and wild type spikes was run in 
two lanes that alternated between samples. Compared with wild type HKU4 spike, the 
downward shift in the band of HKU4 spike bearing the mutated hLCP motif (i.e., 
mutation N762A) is consistent with the removal of glycosylation. Compared with MERS-
CoV spike bearing the re-engineered hPPC motif (i.e., mutation R748S), the upward shift 
in the band of MERS-CoV spike bearing both the re-engineered hPPC and hLCP motifs 
(i.e., mutations R748S/A763N/F764Y/N765T) indicates the introduction of 
glycosylation. 
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Figure 3.3 Processing of MERS-CoV and HKU4 spikes by human and bat lysosomal 
cysteine proteases. 
(A) HKU4 spike bearing no mutation or the re-engineered hLCP motif (N762A) was 
transiently expressed on the surface of HEK293T cells, and subsequently incubated with 
human lysosomal cysteine proteases; (B) MERS-CoV spike bearing either the mutant 
hPPC motif alone (R748S) or both the mutant hPPC and hLCP motifs 
(R748S/A763N/F764Y/N765T) was transiently expressed on the surface of HEK293T 
cells, and subsequently incubated with human lysosomal cysteine proteases; The mutant 
hPPC motif (R748S) was included in MERS-CoV spike to prevent its cleavage by human 
proprotein convertases during the molecular maturation process. After incubation with 
human or bat lysosomal cysteine proteases at pH 5.0 and 37°C for 30 min, both HKU4 
and MERS-CoV spikes with a C-terminal C9 tag were subjected to Western blot using 
anti-C9-tag antibodies.  
    86 
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Figure 3.4 HKU4 and MERS-CoV-spike-mediated pseudovirus entry into HEK293T 
cells. 
(A) HKU4 pseudoviruses bearing no mutation, re-engineered hPPC motif (S746R), re-
engineered hLCP motif (N762A), or both of the re-engineered motifs (S746R/N762A) 
were used to infect HEK293T cells exogenously expressing human DPP4. The infections 
were carried out in the presence or absence of exogenous trypsin. The pseudovirus entry 
efficiencies were characterized as luciferase activity accompanying the entry, and 
normalized against the relative amount of spikes incorporated into pseudovirus particles 
(Fig. 3.2A). The pseudovirus entry mediated by HKU4 spike bearing both of the re-
engineered motifs was taken as 100%. (B) HEK293T cells were pre-treated with the 
following protease inhibitors before being infected by different HKU4 pseudoviruses: 
proprotein convertase inhibitor (dec-RVKR-CMK) for HKU4 pseudoviruses bearing the 
re-engineered hPPC motif (S746R), lysosomal cysteine protease inhibitor (E-64d) for 
HKU4 pseudoviruses bearing the re-engineered hLCP motif (N762A), and both of the 
inhibitors for HKU4 pseudoviruses bearing both of the mutations. (C) MERS-CoV 
pseudoviruses bearing no mutation, mutated hPPC motif (R748S), mutated hLCP motif 
(A763N/F764Y/N765T), or both of the mutated motifs (R748S/A763N/F764Y/N765T) 
were used to infect HEK293T cells exogenously expressing human DPP4. The 
pseudovirus entry mediated by wild type MERS-CoV spike was taken as 100%. (D) 
HEK293T cells were pre-treated with the following protease inhibitors before being 
infected by different MERS-CoV pseudoviruses: proprotein convertase inhibitor (dec-
RVKR-CMK) for MERS-CoV pseudoviruses bearing the mutated hPPC motif (R748S), 
lysosomal cysteine protease inhibitor (E-64d) for MERS-CoV pseudoviruses bearing the 
mutated hLCP motif (A763N/F764Y/N765T), and both of the inhibitors for wild type 
MERS-CoV pseudoviruses. Error bars indicate SEM (n = 4). 
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Figure 3.5 HKU4 and MERS-CoV-spike-mediated pseudovirus entry into Huh-7 
and MRC-5 cells. 
(A) HKU4 pseudoviruses bearing no mutation, re-engineered hPPC motif (S746R), re- 
engineered hLCP motif (N762A), or both of the re-engineered motifs (S746R/N762A) 
were used to infect Huh-7 cells endogenously expressing human DPP4. The pseudovirus 
entry efficiencies were characterized as luciferase activity accompanying the entry, and 
normalized against the relative amounts of spikes incorporated into pseudovirus particles 
(Fig. 3.2A). The pseudovirus entry mediated by HKU4 spike bearing both of the re- 
engineered motifs was taken as 100%. (B) Same as in panel (A), except that MRC-5 cells 
were used. (C) MERS-CoV pseudoviruses bearing no mutation, mutated hPPC motif 
(R748S), mutated hLCP motif (A763N/F764Y/N765T), or both of the mutated motifs 
(R748S/A763N/F764Y/N765T) were used to infect Huh-7 cells endogenously expressing 
human DPP4. The pseudovirus entry mediated by wild type MERS-CoV spike was taken 
as 100%. (D) Same as in panel (C), except that MRC-5 cells were used. The infections 
were carried out in the presence or absence of exogenous trypsin. Error bars indicate 
SEM (n = 4).  
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Figure 3.6 HKU4 and MERS-CoV-spike-mediated pseudovirus entry into bat cells. 
(A) HKU4 pseudoviruses bearing no mutation or re-engineered hLCP motif (N762A) and 
were prepared in HEK293T cells, and then used to infect RSKT cells endogenously 
expressing bat DPP4 (Rhinolophus sinicus bat kidney cells). (B) MERS-CoV 
pseudoviruses bearing no mutation or the mutant hLCP motif (A763N/F764Y/N765T) 
were prepared in HEK293T cells, and then used to infect RSKT cells. RSKT cells were 
pre-treated with indicated concentrations of LCP inhibitor (E-64d) before being infected 
by pseudoviruses. (C) HKU4 pseudoviruses bearing no mutation or re-engineered hLCP 
motif (N762A) were used to infect Tb1-Lu cells (Tadarida brasiliensis bat lung cells) 
exogenously expressing bat DPP4 (GenBank accession number KC249974). (D) MERS-
CoV pseudoviruses bearing no mutation or the mutant hLCP motif 
(A763N/F764Y/N765T) were used to infect Tb1-Lu cells. Tb1-Lu cells were pre-treated 
with LCP inhibitor (E-64d) before being infected by pseudoviruses. 
The pseudovirus entry efficiencies were characterized as luciferase activity 
accompanying the entry, and normalized against the relative amount of spike proteins 
incorporated into pseudovirus particles (Fig. 3.2A). The pseudovirus entry mediated by 
wild type HKU4 spike (for panel A and C) or wild type MERS-CoV spike (for panel B 
and D) in the absence of the inhibitor was taken as 100%. Error bars indicate SEM (n = 
4). 
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Since the discovery of double helix and deciphering of the genetic code in 1950s and 
1960s, DNA was identified as the molecule that carries hereditary traits. It is a widely 
accepted concept that DNA is the “Secret of Life”. But it is protein that embodies this 
genetic information from DNA and builds up living things. All types of living organisms 
depend on the existence of proteins. Proteins make it possible for us to see, hear, taste, 
smell, feel, experience, think and move. Proteins catalyze the life-essential chemical 
reactions in the human body, and protect us from pathogen attacks. However, proteins 
that have served their purpose must be degraded so that their constituent amino acids 
building blocks can be recycled for the synthesis of new proteins. Proteases are the 
scavengers in protein degradation. They play an important part in the metabolic activity 
of the body: life would be impossible without them. 
 
By digestion proteins, proteases participate in all aspects of biological activities. They 
influence DNA replication and transcription, contribute to the processing of cellular 
information, regulate cell proliferation and differentiation, and affects inflammation and 
immunity. The body performs digestion at two levels–outside and inside the cell. 
Digestions outside the cells are accomplished by extracellular proteases and cell surface 
anchored proteases whose active sites are located in the extracellular space. The 
concentration of protein in a cell is regulated by a fine balance of synthesis and 
degradation by lysosomal proteases. Aside from degradation, the other major role of 
proteases in the body is in the activation and maturation of proteins from their inactive 
precursors. Proprotein convertases (PPC) are a family of proteases that participate in this 
    92 
activation process. Cellular proteases sometimes can be hijacked by viruses. With the aid 
of cellular proteases in host cells, virus can bind to the cells and invade cells efficiently. 
 
My thesis research focused on cellular proteases involved in blood pressure regulation 
and coronavirus infection. APA, a cell-surface anchored protease, play a pivotal role in 
blood pressure regulation by regulating the metabolism of vasoactive angiotensin 
peptides. By solving the atomic structure of APA and elucidating the substrate specificity 
of APA in the physiological context, my work sheds light on the biological functions of 
APA, and provides a structural framework for development of APA-targeting drugs for 
antihypertensive therapy. 
 
Virus infection poses a constant threat to human health. Coronavirus has attracted the 
attention from scientific community as well as the public in the last decade due to the 
outbreak of SARS-CoV and MERS-CoV. MERS-CoV utilizes a cell surface protease, 
DPP4, for cell attachment; and exploits PPC and lysosomal proteases for efficient host 
cell entry during its infection process. By characterizing the receptor binding and cell 
entry mechanisms of MERS-CoV and its relatives in bat, this study advocates a possible 
cross-species transmission route of MERS-CoV, and provides novel insights in 
therapeutic discoveries for anti-MERS treatment. 
 
Due to their ubiquitous existence in all kinds of tissues and organs, and prevalence in 
multiple biological processes, proteases are a major focus of attention for the 
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pharmaceutical industry as potential drug targets to treat many life-threating diseases. My 
thesis research brings new perspectives into understanding the diverse roles of cellular 
proteases, and contributes to therapeutic discoveries for the treatment of hypertension and 
virus infection. 
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